MONITORING AND EVALUATION (M&E) PLAN

Health Sector HIV & AIDS Strategic Plan 2017–2022 (HSHP IV)
Citation:
MONITORING AND EVALUATION (M&E) PLAN

Health Sector HIV & AIDS Strategic Plan 2017–2022 (HSHSP IV)

TR-18-302
FOREWORD

The Tanzania HIV Impact Survey (THIS), 2016–2017 (THIS, 2017), showed adult HIV prevalence of 4.7 percent compared to 5.1 percent in 2012. However, even with this decline, the study found that nine out of the 26 regions in the country had HIV prevalence above the national average. Moreover, the study showed a higher HIV prevalence in urban (7.5%) than in rural areas (4.5%) and among women (6.2%) than men (3.1%). Against this background, the Fourth Health Sector HIV and AIDS Strategic Plan, 2017–2022 (HSHSP IV) has been developed with the aim of fast-tracking combination prevention strategies to reduce HIV incidence and eliminate the AIDS epidemic as a public health threat by 2030. The goals of HSHSP IV are to be met through the implementation of the “maximum coverage technical efficiencies” scenario, which matches the country’s epidemiology and current funding landscape. The scenario entails the maximisation of efforts and coverage of HIV prevention and treatment services, with a focus on key and vulnerable populations.

This Health Sector HIV and AIDS Monitoring & Evaluation Plan 2017–2022 (HSHSP IV M&E Plan) has been developed to guide stakeholders on how to monitor and evaluate implementation of the HSHSP IV and determine whether its goals and objectives are being met. The guidance includes definition of indicators for the measurement of expected results (impact, outcomes and outputs), sources of data, frequency of data collection, baseline level, and targets for each indicator and institutions that are responsible for collecting and reporting the data.

The HSHSP IV has 75 indicators in total. The number of indicators by the five strategic areas defined in the strategic plan is as follows: (1) HIV testing services – 4 indicators; (2) HIV prevention services – 15 indicators; (3) treatment, care, and support for PLHIV – 21 indicators; (4) health system strengthening – 26 indicators; and (5) crosscutting interventions – 9 indicators. Seven indicators are identified as core HSHSP IV indicators. The M&E plan underscores the importance of using standard national data collection and reporting tools.

An M&E plan that is not implemented is meaningless. Effective implementation of this M&E plan will provide strategic information for planning and decision-making purposes, including any necessary course correction measures required for the attainment of the “triple 90” global goals, through which 90 percent of people living with HIV will know their status; 90 percent of all people diagnosed with HIV will be enrolled in antiretroviral therapy (ART); and 90 percent of all people receiving ART will attain sustainable viral suppression by the year 2020. All stakeholders, including the National AIDS Control Programme officials and other government officials responsible for planning and implementation of HIV prevention programs, regional and council health management teams, healthcare providers, and national and international nongovernmental organizations supporting HIV interventions are called upon to contribute to the data collection, analysis, dissemination, and use efforts as defined in this plan.

Dr. Mpoki M. Ulisubisya
Permanent Secretary
Ministry of Health, Community Development, Gender, Elderly and Children
ACKNOWLEDGEMENTS

This document is a result of concerted efforts of several organizations and individuals whose contributions we wish to acknowledge. Special acknowledgment is given to the National AIDS Control Programme (NACP) for the strategic leadership of the entire process. The NACP Programme Manager provided overall leadership of the exercise. The Epidemiology and M&E Unit staff played a critical role in the writing and review of several versions of the M&E plan.

We appreciate the contribution of representatives from the following organizations during workshops conducted to review the M&E plan indicators and targets:

- President’s Office – Regional Administration and Local Government (PO-RALG)
- Tanzania Commission for AIDS (TACAIDS)
- United States Centers for Disease Control, Tanzania (CDC)
- United States Department of Defense (DOD)
- Henry M. Jackson Foundation Medical Research International (HJFMRI)/U.S. Military HIV Research Program (MHRP)
- HIV & AIDS implementing partners, including but not limited to Tanzania Health Promotion Support (THPS), ICAP Tanzania, Jhpiego, and Management and Development for Health

We also express special appreciation for the technical assistance and financial support of the United States Agency for International Development (USAID), through the USAID-funded MEASURE Evaluation–Tanzania project. We single out the contributions of the following staff from MEASURE Evaluation–Tanzania to the development of this M&E plan: Willis Odek, Eveline Nguma, Zaddy Kibao, and Kusekwa Sono.

We thank the knowledge management team at MEASURE Evaluation, University of North Carolina at Chapel Hill, for editorial, design, and production services.

Any feedback from experiences in implementing this M&E plan should be channelled to the NACP.

_________________________________

Dr. Leonard Subi

Director for Preventive Services

Ministry of Health, Community Development, Gender, Elderly and Children
CONTENTS

Foreword............................................................................................................................................. 3
Acknowledgements ............................................................................................................................... 6
Contents ................................................................................................................................................ 7
Figures .................................................................................................................................................. 10
Tables ................................................................................................................................................... 10
Abbreviations ........................................................................................................................................ 11
1. Background ...................................................................................................................................... 15
   1.1. HIV and AIDS in Tanzania ......................................................................................................... 15
       1.1.1. HIV Prevalence ..................................................................................................................... 15
       1.1.2. Geographic Heterogeneity of the HIV Epidemic .................................................................. 16
       1.1.3. Sources of New Infections and Risk Factors ....................................................................... 16
       1.1.4. The Fast Track 90-90-90 Amongst People Living with HIV ................................................. 17
   1.2. The Health Sector Strategic Plan, July 2015–June 2020 (HSSP IV) .............................................. 18
       1.2.1. Mission ....................................................................................................................................... 18
       1.2.2. Overall and Specific Objectives .............................................................................................. 19
   1.3. The Fourth Health Sector HIV and AIDS Strategic Plan, 2017–2022 (HSHSP IV) ................. 19
       1.3.1. Vision ......................................................................................................................................... 19
       1.3.2. Mission ....................................................................................................................................... 19
       1.3.3. Goal .......................................................................................................................................... 20
   1.4. Health Sector HIV and AIDS Priority Interventions ................................................................. 20
       1.4.1. HIV Testing Services ............................................................................................................... 20
       1.4.2. HIV Prevention Services ........................................................................................................ 21
       1.4.3. Decentralised and Integrated HIV and AIDS Care, Treatment, and Support Services .... 21
       1.4.4. Building Resilient and Sustainable Systems for Health to Support the National Response ... 21
       1.4.5. Cross-Sector HIV and AIDS Interventions and Other Innovative Investments .............. 21
   1.5. Purpose of the M&E Plan ........................................................................................................... 22
   1.6. Process for the Development of the M&E Plan ....................................................................... 22
   1.7. Target Audience ........................................................................................................................ 22
   1.8. Organisation of the M&E Plan ..................................................................................................... 23
2. Goal and Objectives of the M&E Plan ............................................................................................. 24
2.1. Introduction.................................................................................................................. 24
2.2. Goal........................................................................................................................................ 24
2.3. Objectives.......................................................................................................................... 24
3. The Health Sector HIV and AIDS M&E Framework .............................................................. 25
   3.1. M&E Results Pathway ....................................................................................................... 25
   3.2. HSHSP IV M&E Framework ............................................................................................. 26
   3.3. HSHSP Performance Indicators ...................................................................................... 29
   3.4. HSHSP IV M&E Indicator Matrix .................................................................................... 29
4. The Health Sector M&E System Capacity............................................................................ 32
   4.1. Introduction ..................................................................................................................... 32
   4.2. Health Sector M&E System Strengthening Activities .................................................... 33
5. Health Sector M&E Data Collection Strategy ..................................................................... 35
   5.1. Introduction ..................................................................................................................... 35
   5.2. Routine Data Sources ...................................................................................................... 35
   5.3. Nonroutine Data Sources (Evaluation Data) ................................................................. 36
   5.4. Reporting and Data Flow ................................................................................................. 38
   5.5. Data Management .......................................................................................................... 39
      5.5.1. Data Recording and Checking .................................................................................. 39
      5.5.2. Data Retention .......................................................................................................... 39
      5.5.3. Data Storage and Confidentiality ............................................................................... 39
   5.6. Data Quality Assurance ................................................................................................. 39
6. Stakeholder Roles and Responsibilities.............................................................................. 40
   6.1. Ministry of Health, Community Development, Gender, Elderly and Children
       (MOHCDGEC) provides overall technical leadership guidance, advice, and M&E on the
       implementation of HSHSP IV .............................................................................................. 40
   6.2. National AIDS Control Programme (NACP) ................................................................. 40
   6.3. Research and Academic Institutions ........................................................................... 41
   6.4. President’s Office-Regional Administration and Local Government (PO-RALG) .......... 41
   6.5. Regional Health Management Teams (RHMTs) .............................................................. 41
   6.6. Council Health Management Teams (CHMTs) ............................................................... 42
   6.7. Health Facilities (Hospitals, Health Centres and Dispensaries) .................................... 43
   6.8. Communities .................................................................................................................. 43
   6.9. Implementing Partners .................................................................................................... 43
7. Data Dissemination and Use ............................................................................................... 45
   7.1. Barriers to Data Use ........................................................................................................ 45
7.2. Data Analysis

7.3. Data Dissemination and Use

7.4. Capacity Building

8. Monitoring and Evaluation of Health Sector HIV Plan Implementation

8.1. Annual M&E Operational Plans

8.2. Mid- and End-Term Evaluation

8.3. Assumptions for the Successful Implementation of the HSHSP IV M&E Plan

References

Appendix 1. Summary of HSSSP IV Indicators, by level, in the M&E Results Pathway (Impact, Outcome, and Output)

Appendix 2. Comprehensive HSHSP IV Indicators Matrix

Appendix 3. Health Sector M&E System Strengthening Action Plan
FIGURES

Figure 1: HIV prevalence among adults by region, THIS 2016–2017 ........................................ 16
Figure 2: Performance against the 90-90-90 goals amongst people living with HIV in Tanzania, THIS 2016–2017................................................................................................................................................ 18
Figure 3: Monitoring and evaluation results pathway ................................................................ 26
Figure 4: Organizing framework for a functional national HIV M&E system—12 components...... 33
Figure 5: Health sector HIV and AIDS M&E system .................................................................... 37
Figure 6: Reporting timeline, data flow, and feedback mechanism ............................................. 38

TABLES

Table 1: HSHSP IV results framework .......................................................................................... 27
Table 2: Indicator standards .......................................................................................................... 30
Table 3: Core HSHSP IV indicators ............................................................................................. 31
Table 4: Standard tools for monitoring and responsibility for and frequency of their reporting .... 35
Table 5: Dissemination plan for informational products from the HSHSP IV M&E plan ............ 47
ABBREVIATIONS

ADR  adverse drug reaction
AE   adverse event
AGYW adolescent girls and young women
AIDS acquired immune deficiency syndrome
ANC  antenatal care
ART  antiretroviral therapy
ARV  antiretroviral medicine
CBHS community-based health services
CHMT council health management team
CTC  care, treatment, and support
DBS  dried blood spot
DNA-PCR deoxyribonucleic acid polymerase chain reaction test
DQA  data quality assessments
EID  early infant diagnosis
eMTCT elimination of mother-to-child transmission of HIV
FBO  faith-based organisation
FSW  female sex workers
GARP UNAIDS Global AIDS Response Reporting
GBV  gender-based violence
GF   Global Fund to Fight AIDS, Tuberculosis and Malaria
HBC  home-based care
HC   health centres
HIS  health information system
HIV  human immunodeficiency virus
HMIS Health Management Information System
HMT  Health Management Teams
HRHIS Human Resource for Health Information System
HS   health sector
HSHSP III Third Health Sector HIV and AIDS Strategic Plan, 2013–2017
HSHSP IV Fourth Health Sector HIV and AIDS Strategic Plan, 2018–2022
HSSP IV Fourth Health Sector Strategic Plan, 2015–2020
<table>
<thead>
<tr>
<th>Acronym</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>HTC</td>
<td>HIV testing and counselling</td>
</tr>
<tr>
<td>HTS</td>
<td>HIV testing services</td>
</tr>
<tr>
<td>HVL</td>
<td>HIV viral load</td>
</tr>
<tr>
<td>IBBSS</td>
<td>integrated biological and behavioural surveillance survey</td>
</tr>
<tr>
<td>IP</td>
<td>implementing partner</td>
</tr>
<tr>
<td>IPC</td>
<td>infection prevention and control</td>
</tr>
<tr>
<td>IPT</td>
<td>Isoniazid Preventive Therapy</td>
</tr>
<tr>
<td>ISO</td>
<td>International Organization for Standardization</td>
</tr>
<tr>
<td>JAPR</td>
<td>Joint Annual Programme Review</td>
</tr>
<tr>
<td>KP</td>
<td>key population</td>
</tr>
<tr>
<td>KVP</td>
<td>key and vulnerable population</td>
</tr>
<tr>
<td>LEEP</td>
<td>Loop Electrosurgical Excision Procedure</td>
</tr>
<tr>
<td>LIS</td>
<td>Laboratory Information System</td>
</tr>
<tr>
<td>LTFU</td>
<td>loss to follow-up</td>
</tr>
<tr>
<td>M&amp;E</td>
<td>monitoring and evaluation</td>
</tr>
<tr>
<td>MER</td>
<td>monitoring, evaluation, and reporting</td>
</tr>
<tr>
<td>MESI</td>
<td>M&amp;E Strengthening Initiative</td>
</tr>
<tr>
<td>MOHCDGEC</td>
<td>Ministry of Health, Community Development, Gender, Elderly and Children</td>
</tr>
<tr>
<td>MSM</td>
<td>men who have sex with men</td>
</tr>
<tr>
<td>MTCT</td>
<td>mother-to-child transmission of HIV</td>
</tr>
<tr>
<td>NACP</td>
<td>National AIDS Control Programme</td>
</tr>
<tr>
<td>NBS</td>
<td>National Bureau of Statistics</td>
</tr>
<tr>
<td>NBTS</td>
<td>National Blood Transfusion Services</td>
</tr>
<tr>
<td>NCD</td>
<td>noncommunicable disease</td>
</tr>
<tr>
<td>NGI</td>
<td>PEPFAR's Next Generation Indicators</td>
</tr>
<tr>
<td>NGOs</td>
<td>nongovernmental organisations</td>
</tr>
<tr>
<td>NHLQATC</td>
<td>National HIV Laboratory Quality Assurance and Training Centre</td>
</tr>
<tr>
<td>NMSF III</td>
<td>Tanzania Third National Multi-Sectoral Strategic Framework for HIV and AIDS</td>
</tr>
<tr>
<td></td>
<td>2013/2014–2017/2018</td>
</tr>
<tr>
<td>OI</td>
<td>opportunistic infections</td>
</tr>
<tr>
<td>OPD</td>
<td>outpatient department</td>
</tr>
<tr>
<td>OVC</td>
<td>orphans and vulnerable children</td>
</tr>
<tr>
<td>PEPFAR</td>
<td>United States President's Emergency Plan for AIDS Relief</td>
</tr>
</tbody>
</table>
PLHIV  people living with HIV
PO-RALG President’s Office-Regional Administration and Local Government
PMTCT prevention of mother-to-child transmission of HIV
PO-PSM President’s Office-Public Services Management
PPM planned preventive maintenance
PrEP pre-exposure prophylaxis
PWID people who inject drugs
PWUD people who use drugs
QI quality improvement
RCH reproductive and child health
RHMT regional health management team
RMO Regional Medical Officer
RTI reproductive tract infection
SA strategic area
SLIPTA Stepwise Laboratory Improvement Process towards Accreditation
SLMTA Strengthening of Laboratory Management towards Accreditation
SO strategic outcome
SOP standard operating procedures
SPD Sentinel Panel of Districts
STI sexually transmitted infections
TACAIDS Tanzania Commission for AIDS
TB Tuberculosis
TBD to be decided
TDHS Tanzania Demographic and Health Survey
TFDA Tanzania Food and Drug Authority
THIS Tanzania HIV Impact Survey
THMIS Tanzania HIV/AIDS and Malaria Indicator Survey
TrainSMART training system monitoring and reporting tool
TSPA Tanzania Service Provision Assessment
TTI transfusion-transmitted infection
UNAIDS Joint United Nations Programme on HIV and AIDS
UNGASS United Nations General Assembly Special Session
USAID United States Agency for International Development
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>VIA</td>
<td>visual inspection with acetic acid</td>
</tr>
<tr>
<td>VMMC</td>
<td>voluntary male medical circumcision</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>WHO/AFRO</td>
<td>World Health Organization/Regional Office for Africa</td>
</tr>
</tbody>
</table>
1. BACKGROUND

This chapter presents an overview of the HIV and AIDS situation in Tanzania and the Tanzania Fourth Health Sector HIV/AIDS Strategic Plan, 2017–2022 (HSHSP IV), which provides the context for the monitoring and evaluation (M&E) plan. The HSHSP IV seeks to lead Tanzania towards the attainment of the “triple 90” global goals, through which 90 percent of people living with HIV will know their status; 90 percent of all people diagnosed with HIV will be enrolled in antiretroviral therapy (ART); and 90 percent of all people receiving ART will attain sustainable viral suppression by the year 2020.

1.1. HIV and AIDS in Tanzania

1.1.1. HIV Prevalence

HIV prevalence has steadily declined over the past decade, from 7 percent in 2003 to 4.7 percent in 2016.¹ HIV prevalence in Tanzania is characterized by significant heterogeneity across age, gender, socioeconomic status, and geographic location, which implies differentials in the risk of transmission. The current HIV prevalence ranges from less than 1 percent in Lindi to 11.4 percent in the Njombe Region.

The Joint United Nations Programme on HIV/AIDS (UNAIDS) estimates that in 2015 there were 1,400,000 people living with HIV (PLHIV) in Tanzania. Of this number, 120,000 were children below age 15 and 750,000 were women ages 15 or over. The Tanzania HIV Impact Survey (THIS), 2016–2017 (THIS, 2017) shows that HIV prevalence in women ages 15–49 is twice that in men of the same age. The prevalence of HIV is less than 2 percent amongst those ages of 15–19 years for both males and females; it then increases with age for both sexes. The age disparities in new HIV infections suggest an increase in numbers of new infections amongst younger populations.

UNAIDS and partners developed the AIDS Impact Module using Spectrum software to assist countries in monitoring their HIV epidemics. This software uses HIV surveillance, survey, and programme data, combined with demographic data, to generate historical trends and short-term projections of key indicators. These indicators, including the number of people living with HIV, the number of new infections, the number of pregnant women infected with HIV, mortality due to AIDS, and treatment coverage, are useful in assessing epidemic trends and the overall impact of the AIDS response, and in planning for future healthcare services and pharmaceutical needs.

The 2015 AIDS Impact Module estimates indicate that the mother-to-child transmission (MTCT) of HIV rate had decreased to 7.6 percent at the end of breastfeeding. Available data suggest that HIV infection rates begin to rise much earlier in girls than boys, and these differences persist until much later in adulthood. Given the epidemiologic evidence of their early and heightened vulnerability, addressing sexual health services and age-tailored HIV prevention for adolescent girls is a priority.

---

1.1.2. Geographic Heterogeneity of the HIV Epidemic

Mainland Tanzania is demarcated into 26 administrative regions, of which 9 show HIV prevalence above the national average, according to the THIS 2016–2017 study. In general, HIV prevalence is higher in urban (7.5%) than in rural areas (4.5%). The Njombe Region has the highest HIV prevalence estimate (11.4%), followed by Iringa (11.3%) and Mbeya (9.3%). The Lindi Region has the lowest HIV prevalence, at less than 1 percent. There is also evidence from programme data of marked heterogeneity amongst the constituent districts of the regions. Specifically, some high prevalence districts and hotspots have been identified within regions that formerly had relatively low HIV prevalence. Figure 1 depicts regional HIV prevalence estimates based on the THIS 2016–2017 study.

Figure 1. HIV prevalence amongst adults by region, THIS 2016–2017

1.1.3. Sources of New Infections and Risk Factors

The 2014 Modes of HIV Transmission (MOT) study in Tanzania mainland showed that the majority of new infections in Tanzania occur in the context of stable heterosexual relationships (38.8%) and casual heterosexual sex (28.9%). The other sources of infection are clients of sex workers (8.7%),
partners of people engaged in casual sex (7.6%), men who have sex with men (MSM) (6.8%),
partners of sex worker clients (3.3%), people who inject drugs (PWID) (2.1%), and sex workers
(1.3%). To significantly reduce HIV incidence, interventions are being targeted towards the major
sources of new infections—heterosexual relationships, casual heterosexual sex, clients of sex
workers, and MSM.

Tanzania has not yet conducted a nationally representative integrated biological and behavioural
surveillance survey (IBBSS) to estimate the prevalence of HIV and the size of key and vulnerable
populations (KVPs). However, there is a national consensus report that provides national estimates
and prevalence for female sex workers (FSWs), MSM, and PWID. To more accurately gauge the
proportionate burden of different KVP groups, there is a need to conduct national mapping and
population size estimations for KVPs.

1.1.4. The Fast Track 90-90-90 Amongst People Living with HIV

Achievement of the fast track 90-90-90 goals amongst PLHIV is an ambitious target aimed at helping
to end the AIDS epidemic. It is anticipated that by 2020, 90 percent of all PLHIV will know their HIV
status; 90 percent of all people diagnosed with HIV will receive sustained ART; and 90 percent of all
people receiving ART will attain sustainable viral suppression.

In Tanzania, 52.2 percent of PLHIV ages 15 to 64 years (55.9 and 45.3 percent amongst females and
males, respectively) know their HIV status. Amongst PLHIV ages 15 to 64 who know their HIV status,
90.9 percent (92.9 and 86.1 percent amongst females and males, respectively) self-report their
current use of ART. Amongst PLHIV ages 15 to 64 who self-report current use of ART, 87.7 percent
(89.2 and 84.0 percent amongst females and males, respectively) are virally suppressed, based on
the THIS 2016–2017 study (see Figure 2).

---

and HIV prevalence in Tanzania.
Viral load suppression among HIV-positive individuals in Tanzania is highest amongst older adults, with 64 and 62 percent of females and males ages 55 to 64, respectively, virally suppressed. The corresponding estimates are 59 percent and 36 percent amongst females and males ages 15–54, respectively. Gender disparity in viral load suppression is greater amongst younger adults, with 51 percent of females ages 25 to 34 virally suppressed, compared to 26 percent of men in the same age group. Amongst HIV-positive adults ages 15 and older, viral load suppression varies geographically across Tanzania, ranging from 67 percent in Kagera and Kilimanjaro to 40 percent in Shinyanga and 29 percent in Arusha (THIS, 2016–2017).

1.2. The Health Sector Strategic Plan, July 2015–June 2020 (HSSP IV)

The current National HIV response is guided by the Fourth Health Sector Strategic Plan, 2015–2020 (HSSP IV) and the Fourth Health Sector HIV and AIDS Strategic Plan, 2017–2022 (HSHP IV). The health and social welfare sector follows the overall Tanzania Development Vision 2025, which seeks to transform Tanzania into a middle-income country status, characterised by a high-quality livelihood, amongst other attributes, by 2025. Derived from this overall vision, the vision of the health and social welfare sector is “to have a healthy society with improved social wellbeing that will contribute effectively to individual and national development.”

1.2.1. Mission

The mission of the health and social welfare sector is “the provision of basic health and social welfare services that are of good quality, equitable, accessible, affordable, sustainable, and gender sensitive.”
1.2.2. Overall and Specific Objectives

The overall objective of HSSP IV is to reach all households with essential health and social welfare services, meeting as much as possible expectations of the population and objective quality standards, and applying evidence and efficient channels of service delivery.

The specific objectives of HSSP IV are as follows:

1. Achieve objectively measurable quality improvement (QI) of primary healthcare services, delivering a package of essential services in communities and health facilities
2. Improve equitable access to services in the country by focusing on geographic areas with higher disease burdens and on vulnerable groups in the populations with higher risk
3. Achieve active community partnership through intensified interactions with the population for improvement of health and social well-being
4. Achieve a higher rate of return on investment by applying modern management methods and innovative partnerships

To improve the social determinants affecting health and welfare, the health and social welfare sector will achieve close collaboration with other sectors and advocate for inclusion of health promoting and health protecting measures in other sectors’ policies and strategies. The health sector will mobilise nongovernmental and private partners to promote health and well-being through their strategies.

1.3. The Fourth Health Sector HIV and AIDS Strategic Plan, 2017–2022 (HSHSP IV)

The HSHSP IV is geared to fast tracking combination prevention strategies to reduce HIV incidence and eliminate the AIDS epidemic as a public health threat by 2030. In implementing HSHSP IV, Tanzania has chosen the “maximum coverage technical efficiencies” scenario, which matches the country’s epidemiology and current funding landscape. The scenario entails the maximisation of efforts and coverage of HIV prevention and treatment services, with a focus on KVPs. This strategy is expected to accelerate progress towards attaining the global sustainable development goals (SDGs)—specifically, SDG 3, which aims to end the epidemics of AIDS, tuberculosis (TB), malaria, and neglected tropical diseases, and combat hepatitis, water-borne diseases, and other communicable diseases by 2030. The HSSP IV provides guidance for the mission and goals of all health sector interventions, including the national health sector HIV response.

1.3.1. Vision

The vision of HSHSP IV is an HIV-free society in which new infections are halted and people living with HIV or affected by HIV and AIDS receive quality services and support.

1.3.2. Mission

The mission of HSHSP IV is to provide a results-oriented framework to lead and guide the decentralised health sector HIV response in the intensification, optimisation, and scaling up of quality evidence-based interventions for HIV prevention, care, treatment, and support services for PLHIV to facilitate the attainment of the “triple 90” targets in Tanzania.
1.3.3. Goal

The goal of the HSHSP IV is to increase the coverage of HIV and AIDS services in the general population and subpopulations to ensure the following by 2020:

- Universal access is available to combination prevention services designed to reduce new HIV infections, HIV-related mortality, and stigma and discrimination
- 90 percent of people living with HIV will know their status
- 90 percent of all people diagnosed with HIV are enrolled, followed up on, and in receipt of timely and efficacious ART
- 90 percent of all people receiving ART will attain sustainable viral suppression
- The capacity of the health system is strengthened to support quality HIV and AIDS interventions, and foster integration within the health sector

1.4. Health Sector HIV and AIDS Priority Interventions

The HSHSP IV interventions are grouped into five strategic areas: (1) HIV testing services (HTS); (2) HIV prevention services; (3) treatment, care, and support for PLHIV; (4) health system strengthening (HSS); and (5) crosscutting interventions. In the previous strategic plans, HIV testing and counselling was part of HIV prevention. However, with the new focus on a “Treat All” approach, HTS is regarded as an entry point for treatment, care, and support services for PLHIV and thus considered as a strategic area on its own. This section highlights each strategic area, describing the current situation and priority strategies. Each strategic area has corresponding strategic objectives and indicators, summarized in Appendix 1.

1.4.1. HIV Testing Services

HTS are provided through a mix of modalities, including client-initiated HIV testing and counselling (CITC) and provider-initiated testing and counselling (PITC) provided within health facilities and community settings. In 2016, 7.4 million individuals were tested for HIV, an increase from the 2.5 million recorded in 2014. The annual target for 2016 was nearly 5.5 million tests. According to a 2012 study, the proportion of people who had been tested for HIV and received test results in Mainland Tanzania was 62 and 47 percent amongst women and men, respectively (THMIS, 2012). By end of 2016, about 63 percent of PLHIV (the minimum number who knew their status) in Tanzania were already enrolled in ART care. Some of the gaps and challenges observed in implementing HTS activities include (1) recurrent stockouts of HIV rapid test kits; (2) an inadequate health workforce for maximum coverage of HIV testing according to set standards; (3) low uptake of HTS amongst adolescents, children, and men; and (4) poor data collection systems. Amongst the strategies in the HSHSP IV to improve HTS are (1) intensification of existing and identification of new alternative service delivery models, such as the scale-up of HTS in regions with high HIV prevalence and incidence and low knowledge of HIV status; (2) scale-up of targeted HIV testing, including index client HIV testing (at facility and community levels), community home-based HTS, and mobile HTS that targets hotspots, prisons, orphanages, and selected workplaces; and (3) improved monitoring of HTS.
1.4.2. HIV Prevention Services

HIV prevention services under the HSHSP IV are focused on averting new HIV infections. In implementing the HSHSP IV, Tanzania recognizes the need to balance both HIV prevention and treatment efforts, because although treatment is considered part of prevention as a result of its overarching impact in reducing viral load and thus transmission, effective prevention interventions are at least equally if not more important. HSHSP IV seeks to intensify prevention interventions with particular focus on condom programming; male circumcision; and programmes for KVPs, including adolescent girls and young women (AGYW).

1.4.3. Decentralised and Integrated HIV and AIDS Care, Treatment, and Support Services

Access to ART and other care, treatment, and support (CTC) services (comprehensive HIV care) has improved the health and well-being of PLHIV by reducing both mortality and morbidity associated with HIV. The number of PLHIV accessing CTC services has continued to increase, and the majority will be on ART going forward. With the adoption of a “Treat All” approach, facilities and health systems will be faced with increased numbers of PLHIV seeking care, and with different needs. The HSHSP IV emphasises strengthening the linkage of HIV testing services to care for all HIV-positive individuals. This goal is to be addressed through early treatment initiation and adherence to treatment amongst children, adolescents, and young women and adults.

1.4.4. Building Resilient and Sustainable Systems for Health to Support the National Response

Over the years, Tanzania has made progress towards universal access to HIV and AIDS services provided through community- and health facility-based interventions. In health facilities, these services are provided through CTC services and reproductive and child health (RCH) clinics (Option B+ for pregnant women). The number of health facilities providing ART services has increased from 1,176 out of 6,342 (18%) in 2012 to 6,155 out of 7,494 (82%) by December 2016. Strong and resilient community and health systems are needed to support a sustainable national response to HIV and AIDS. In strengthening health systems, HIV-related infrastructure, service delivery, logistics systems, and human resource capacities need to be built into the national programme and not dealt with in isolation. The HSHSP IV will continue to support the improvement and strengthening of the health system infrastructure within the World Health organization (WHO) health system framework, which recognizes the influence of human resources for health (HRH), health information systems (HIS), medicines and technologies, health financing, and leadership and governance on the ability to deliver quality health services.

1.4.5. Cross-Sector HIV and AIDS Interventions and Other Innovative Investments

Reduction of stigma and discrimination are core elements in the national HIV/AIDS response. The scale-up of care and treatment services has enabled individuals to return to normal lives and contribute to family and national income while partly addressing stigma associated with chronic illness and disability amongst PLHIV. However, there is still a need for more strategic approaches in addressing HIV stigma and discrimination to improve access to health services because there is a close link between stigma and poor adherence to and retention in ART care. The HSHSP IV highlights the importance of addressing legal, social, and policy environmental
factors that contribute to stigma and discrimination, and impede efforts aimed at gender-based violence (GBV) prevention.

1.5. **Purpose of the M&E Plan**

To determine the extent to which HSHSP IV results are being achieved, there is need for systematic collection of data on the various strategies being applied and services provided. The purpose of this M&E plan is to provide guidance for tracking health sector HIV/AIDS programmes and outcomes as per the HSHSP IV. This M&E plan guides stakeholders on how to monitor and evaluate implementation of the HSHSP IV, and determine whether its goals and objectives are being met. The guidance includes definition of indicators for the measurement of expected results (impact, outcomes, and outputs), sources of data, frequency of data collection, baseline level and targets for each indicator, and institutions responsible for collecting and reporting the data.

1.6. **Process for the Development of the M&E Plan**

The M&E plan was developed through a consultative process. Its development was coordinated by the National AIDS Control Programme (NACP), with technical support from MEASURE Evaluation Tanzania. The specific processes involved were as follows:

**Step 1:** MEASURE Evaluation, jointly with NACP, conducted a desk review of key documents that included HSHSP IV and global HIV M&E reference documents, such as PEPFAR 3.0, United Nations General Assembly Special Session (UNGASS) on HIV/AIDS indicators, UNAIDS Global AIDS monitoring indicators, Global Fund (GF) M&E guidelines, and WHO strategic information guidelines for HIV in the health sector. This desk review assisted in the identification of appropriate indicators for monitoring and evaluating HSHSP IV’s performance, which were written up in the first draft of the M&E plan.

**Step 2:** A five-day workshop was conducted with NACP and other stakeholders to review the draft indicators for the M&E plan. This review workshop entailed the following tasks:

a. Review of the HSHSP IV and identification of indicators (impact, outcome, output, process, and targets) provided in the document, and gaps in indicators for any of the identified programme strategies/areas
b. Review of definitions for all the indicators, ensuring their alignment with definitions in key national and global M&E reference documents
c. Review of all data sources and availability of appropriate data collection tools
d. Setting of baseline levels and targets for each indicator

**Step 3:** MEASURE Evaluation Tanzania worked with a small taskforce comprising staff from NACP and other implementing partners (IPs) to incorporate inputs from the review workshop into advanced drafts and the final version of the M&E plan.

1.7. **Target Audience**

The target audience for this M&E plan includes the following:

- National AIDS programme officers
- Government officials responsible for planning and implementation of HIV prevention programmes
- Regional health management teams (RHMTs), council health management teams (CHMTs), and health facilities implementing the HIV/AIDS interventions
- Development partners
- Other key stakeholders from nongovernmental organisations (NGOs) and academic institutions
- Healthcare providers
- Other organisations responsible for planning and implementation of HIV prevention and treatment services

1.8. Organisation of the M&E Plan

This M&E plan is organised into eight chapters, beginning with this introductory chapter. Chapter 2 presents the goal and objectives of the M&E plan, M&E framework, health sector M&E system, and HSHSP IV outcome targets. Chapter 3 outlines the national health sector HIV/AIDS M&E framework, including performance indicators to be measured by multiple stakeholders. Chapter 4 discusses health sector M&E capacity. Chapter 5 describes the M&E data collection strategy, including coordination of data collection, data flow, reporting, and management. Chapter 6 outlines stakeholder roles and responsibilities in the implementation of the M&E plan, and Chapter 7 discusses strategies for promoting data use and dissemination. Chapter 8 concludes with strategies for monitoring and evaluating the implementation of the M&E plan.
2. GOAL AND OBJECTIVES OF THE M&E PLAN

2.1. Introduction

The NACP is mandated to coordinate the national health sector response to the HIV/AIDS epidemic within the national multisectoral HIV coordination structure led by the Tanzania Commission for AIDS (TACAIDS). Ensuring a functional M&E system is in keeping with the internationally accepted “Three Ones” principles to better coordinate the national HIV/AIDS response. The “Three Ones” principles are as follows:

1. One agreed national coordinating authority to steer the multisectoral response
2. One agreed-upon national strategic framework
3. One agreed-upon national M&E framework

In line with these principles, this M&E plan advocates for a harmonised M&E framework, system, and reporting process.

2.2. Goal

The goal of the health sector HIV/AIDS M&E plan is to facilitate the collection of essential data of high quality and promote an environment of data sharing and use for improved outcomes within the health sector’s HIV/AIDS response.

2.3. Objectives

The specific objectives of the M&E plan are as follows:

- Provide guidance on gathering and reporting data essential for monitoring and evaluating the implementation of the HSHSP IV
- Strengthen the national HIV/AIDS health sector M&E system
- Improve the availability and use of routine HIV/AIDS data in decision-making processes
- Strengthen partnerships and coordination for M&E at national and subnational levels
3. THE HEALTH SECTOR HIV AND AIDS M&E FRAMEWORK

This chapter describes the M&E results pathway and presents the HSHSP IV results framework and a summary of impact and outcome performance indicators for the HSHSP IV.

3.1. M&E Results Pathway

M&E is concerned with the efficiency, effectiveness, and impact of interventions. Efficiency focuses on the application of resources (people, money, skills, and time) to achieve programme goals and objectives. Effectiveness is concerned with the extent to which programme activities bring about desired changes in the lives of the people and communities targeted. Impact relates to the long-term programme results from a concerted response to a problem.

Monitoring is the routine or regular assessment of ongoing activities and progress being made in a programme or project. Evaluation, in contrast, is the episodic assessment of overall achievements and the extent to which they can be attributed to specific interventions. Monitoring looks at what is being done, whereas evaluation examines what has been achieved (UNAIDS, 2002). Evaluation draws from data generated by the monitoring system and links this information to the primary beneficiaries to determine the impact of programmes. Monitoring should be integrated within the programme management system.

An M&E framework is designed to help provide data or evidence that programme activities are meeting the objectives of efficiency and effectiveness, and contributing to impact. The common M&E framework considers developmental change as a chain of interrelated components consisting of inputs, processes, outputs, outcomes, and impacts.

Inputs are the people, training, equipment, and resources put into a programme to achieve the delivery of services.

Processes are the activities or services delivered, including HIV/AIDS prevention, care, and support services, to either improve the well-being of beneficiaries or change their behaviours.

Outputs are immediate results of the processes—for example, the number of trained staff or stock levels of essential drugs and commodities.

Outcomes are changes in behaviour or skills, especially safer HIV prevention practices and increased ability to cope with HIV/AIDS.

Impact relates to the long-term programme results—for example, reduced new HIV infections or the improved well-being of people living with HIV.

Inputs are transformed into outputs through activities undertaken or services delivered. The transformation of inputs into outputs entails a process which requires attention to quality, unit costs, access, and coverage of services. M&E focusing on inputs, the process of their transformation, and outputs is also referred to as “process monitoring,” in contrast to outcomes/effectiveness and impact evaluation. Effectiveness or outcomes and impact evaluations often require targeted studies conducted at the start of a programme and repeated after a considerable period of programme implementation, usually with a control or comparison group. An outcomes evaluation or assessment seeks to determine whether, and by how much, programme activities are achieving their intended effects in the target population. Impact evaluation seeks to determine the magnitude of change that can reliably be attributed to a programme intervention. Figure 3 depicts the M&E results pathway.
As depicted in the results pathway or cycle, the higher the results cycle, the fewer organisations are involved in M&E. Input and output data are normally collected by all programme implementers. Many implementing partners should collect some process data, but far fewer will assess outcomes. Even fewer implementing partners and studies are normally required to assess impact (UNAIDS, 2002).

3.2. HSHSP IV M&E Framework

Table 1 below presents the HSHSP IV Results Framework, with an overall description of the goal, strategic areas, and strategic outcomes. The interventions are organised into five strategic areas (SAs), each with a range of 2 to 10 strategic outcomes (SOs). The implementation of activities under each of the five SAs will result in increased coverage of HIV/AIDS services in the general population and subpopulations for the realisation of the 90-90-90 targets by 2020.
Table 1. HSHSP IV results framework

<table>
<thead>
<tr>
<th>Strategic Area (SA) 1: HIV testing services</th>
<th>SA 2: Prevention of new HIV infections</th>
<th>SA 3: Facility-based care and support for PLHIV</th>
<th>SA 4: Building resilient and sustainable systems for health to support the national response</th>
<th>SA 5: Cross-sector HIV/AIDS interventions and other innovative investments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strategic Outcome (SO) 1.1: 90% of people living with HIV are aware of their status by 2022</td>
<td>SO 2.1: 85% of women and men engaged in multiple sexual partnerships report use of a condom at last sexual intercourse</td>
<td>SO 3.1: By 2022, 95% of all adults (&gt;15) diagnosed with HIV will be on ART</td>
<td>SO 4.1: RHMTs, CHMTs, and health facilities have active QI teams that oversee the implementation, documentation, and reporting of quantitative data on the quality of HIV/AIDS services</td>
<td>SO 5.1: Proportion of PLHIV who report experiencing stigma and discrimination from healthcare providers reduced from 40% to zero by 2022</td>
</tr>
<tr>
<td>SO 1.2: All people (100%) who are identified to be HIV positive during community and facility HTS are linked to HTS services by 2022</td>
<td>SO 2.2: Increased access and use of HIV services by KVP</td>
<td>SO 3.2: All children under 15 years initiated and 90% retained on ART by 2022</td>
<td>SO 4.2: Uninterrupted supply of medicines and commodities for sexually transmitted infections (STIs)/reproductive tract infections (RTIs), HIV, and AIDS at all levels by 2022</td>
<td>SO 5.2: The adoption of safer sexual practices</td>
</tr>
<tr>
<td>SO 2.3: 90% male circumcision rate attained by all regions by 2022</td>
<td>SO 3.3: Reduction of MTCT of HIV from an estimated 8% at the end of breastfeeding in 2015 to 4% by 2022</td>
<td>SO 4.3: Commodity management and logistical information will be generated and used at different levels of the health delivery system to improve decision-making</td>
<td>SO 5.3: Increased uptake of comprehensive HIV/AIDS prevention, treatment, care, and support services</td>
<td></td>
</tr>
<tr>
<td>SO 2.4: The incidence of STIs in the general population and syphilis amongst</td>
<td>SO 3.4: By 2022, the burden of other HIV co-infections and co-morbidities</td>
<td>SO 4.4: Improved tracking of adverse drug effects</td>
<td>SO 5.4: Increased access to comprehensive workplace interventions</td>
<td></td>
</tr>
</tbody>
</table>

Goal
Increase coverage of HIV and AIDS services in the general population and subpopulations to ensure the following by 2020:

1. There will be universal access to combination prevention services designed to reduce new HIV infections, HIV-related mortality, and stigma and discrimination
2. 90% of people living with HIV will know their status
3. 90% of all people diagnosed with HIV will be enrolled, followed up, and receive timely and efficacious highly active antiretroviral therapy
4. 90% of all people receiving ART will attain sustainable viral suppression
5. The capacity of the health system is strengthened to support quality HIV/AIDS interventions and foster integration within the health sector
<table>
<thead>
<tr>
<th>Objective</th>
<th>Target</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pregnant women</td>
<td>Reduced by 50% by 2022</td>
<td>amongst PLHIV reduced by 50 percent of the 2016 level</td>
</tr>
<tr>
<td>Focusing on HIV, TB, and Hepatitis B virus (HBV) prevention, care, and support services by employees</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SO 2.5: All (100%) donated blood units will be screened for transfusion-transmitted infections (TTIs) (HIV, HBV, Hepatitis C [HCV], and syphilis) as per the WHO quality assurance procedure by 2022</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SO 3.5: By 2022, 95 percent of all PLHIV who are on ART achieve viral suppression</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SO 4.5: Quality laboratory services provided for HIV/AIDS clients at all levels</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SO 5.5: Reduction of new HIV infection amongst adolescents and young women by 50% by 2022</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SO 2.6: By 2022, 60 percent of female clients 30–50 years screened for cervical cancer using visual inspection with acetic acid (VIA) and cryotherapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SO 3.6: Improved identification, retention, adherence, and psychosocial support to PLHIV through community-based HIV and AIDS services</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SO 4.6: Uninterrupted HIV services as a result of timely planned preventive maintenance (PPM) of laboratory and other healthcare equipment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SO 5.6: 95 percent of adolescents living with HIV will be on ART by 2022</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SO 3.7: Improved identification, retention, adherence, and psychosocial support to PLHIV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SO 4.7: A well-regulated, monitored, and evaluated programme with up-to-date research outcomes relevant to HIV/AIDS that addresses improved data quality and informs programme performance</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SO 5.7: Improved male involvement in HIV prevention, care, treatment, and support for their own health and the health of their partners and families</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SO 4.8: Strengthened community participation for quality community-based health services</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SO 5.8: Reduced HIV-associated sexual violence and GBV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SO 5.9: Mitigate effects of GBV on survivors, especially women and young people</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
3.3. HSHSP Performance Indicators

The development of a results-based M&E plan entails six essential actions:

1. Formulating outcomes and goals
2. Selecting outcome indicators to monitor
3. Gathering baseline information for each indicator
4. Setting specific targets to reach and the timeline for their realisation
5. Regularly collecting data to assess whether the targets set are being reached
6. Analysing, reporting, and using results for ongoing decision making (Kusek and Rist, 2004)

The formulation of outcomes and goals, and selection of outcome indicators were achieved partly during the HSHSP IV development process and were refined in this M&E plan. Gathering baseline data and setting targets are part of the M&E plan development process. Regularly collecting data to assess whether targets are being met requires clear procedures for data collection, management, analysis, and use in both routine data collection systems and periodic surveys. This M&E plan addresses all of these dimensions.

3.4. HSHSP IV M&E Indicator Matrix

An indicator is a quantitative or qualitative variable that provides a valid and reliable way to measure achievement, assess performance, or reflect changes connected to an intervention. An indicator should reveal whether progress has been made towards expected or planned results in quantity, quality, and timeliness. Unlike performance objectives, an indicator does not specify a level of achievement.

The HSHSP IV identifies seven priority indicators. In addition, there are indicators for measuring performance against each of the strategic outcomes. The identification of indicators for the HSHSP IV has been done carefully to ensure alignment with global M&E reference documents. The indicator prioritisation process was guided by the six criteria identified by the UNAIDS Monitoring and Evaluation Reference Group, as highlighted below in Table 2.
Table 2. Indicator standards

<table>
<thead>
<tr>
<th>Indicator standards: Operational guidelines for selecting indicators for the HIV response</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Standard 1: The indicator is needed and useful</strong></td>
</tr>
<tr>
<td>An indicator must provide data that are required and will be used by stakeholders in planning and decision making.</td>
</tr>
<tr>
<td><strong>Standard 2: The indicator has technical merit</strong></td>
</tr>
<tr>
<td>An indicator must have substantive merit by measuring something of significance and importance within a particular field and be sufficiently sensitive to detect changes in performance. In addition, an indicator must have a monitoring merit or reliability. The indicator must be able to produce the same or very similar results, even if measured by different instruments, procedures, or observers.</td>
</tr>
<tr>
<td><strong>Standard 3: The indicator is fully defined</strong></td>
</tr>
<tr>
<td>The purpose and rationale of an indicator must be clear, as well as the methods for its measurement, including any disaggregation. The numerators and denominators of the indicator must be specified as appropriate, and the frequency of data collection defined. Equally important is the clarity of the interpretation of the indicator.</td>
</tr>
<tr>
<td><strong>Standard 4: It is feasible to collect and analyse data for this indicator</strong></td>
</tr>
<tr>
<td>The systems and mechanisms for collecting, interpreting, and using data for the indicator, such as surveys, need to be in place. It is also important to consider the financial and human resources required for collecting data for the indicator.</td>
</tr>
<tr>
<td><strong>Standard 5: The indicator has been field tested or used in practice</strong></td>
</tr>
<tr>
<td>An indicator should have been field tested and reviewed for data availability.</td>
</tr>
<tr>
<td><strong>Standard 6: The indicator set is coherent and balanced overall</strong></td>
</tr>
<tr>
<td>A good set of indicators should give an overall picture of the adequacy or otherwise of the response being measured. Indicator sets should cover all key elements of the response being assessed, ensuring an appropriate mix of indicators to assess inputs, outputs, outcomes, and impacts.</td>
</tr>
</tbody>
</table>

The HSHSP IV has 75 indicators in total. The number of indicators by SA is as follows: SA 1 (4); SA 2 (15); SA 3 (21); SA 4 (26); and SA 5 (9). The following seven indicators in Table 3 below are identified as core HSHSP IV indicators.
### Table 3. Core HSHSP IV indicators

<table>
<thead>
<tr>
<th>Indicator reference number (refer to Appendix 2)</th>
<th>Indicator</th>
<th>Indicator level</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.3</td>
<td>Percentage of young people ages 15–24 years living with HIV</td>
<td>Impact</td>
</tr>
<tr>
<td>2.2</td>
<td>Percentage of members of KVPs who reported using a condom during their last high-risk sexual encounter</td>
<td>Outcome</td>
</tr>
<tr>
<td>3.1</td>
<td>Number of AIDS-related deaths per 100,000 population</td>
<td>Impact</td>
</tr>
<tr>
<td>3.5</td>
<td>Percentage of adults and children with HIV known to be on treatment 12 months after initiation of ART</td>
<td>Outcome</td>
</tr>
<tr>
<td>3.7</td>
<td>Number and percentage of people living with HIV and on ART who are virologically suppressed (amongst all those currently on treatment who received a viral load measurement regardless of when they started ART)</td>
<td>Outcome</td>
</tr>
<tr>
<td>3.8</td>
<td>Estimated percentage of child HIV infections from HIV-positive women delivering in the past 12 months</td>
<td>Impact</td>
</tr>
<tr>
<td>3.15</td>
<td>Percentage of HIV-infected pregnant women receiving antiretroviral medicines (ARVs) to reduce the risk of MTCT of HIV</td>
<td>Outcome</td>
</tr>
</tbody>
</table>

A summary of all the indicators is provided in Appendix 1. A comprehensive indicator matrix with indicator definitions is included in Appendix 2. The indicator matrix is intended to facilitate the tracking of progress towards the impact, outcomes, and realisation of outputs. The matrix provides the following information:

- **Strategic area and corresponding interventions**
- **Indicators for measuring impacts, outcomes, and outputs**
- **Definition for each indicator regarding the required numerator and denominator**
- **Factors of interest for disaggregating data on each indicator (for example, sex, age, region, etc.)**
- **The source of the indicator, including both national (such as HSHSP IV, HSHSP III, etc.) and global (e.g., PEPFAR MER 2.0, WHO, etc.)**
- **The data sources; this information defines existing initiatives for collection of data that respond to each indicator, including routine data sources, such as the health management information system (HMIS) and special or periodic studies (e.g., Demographic and Health Surveys, AIDS Indicator Surveys, etc.)**
- **Frequency of data collection**
- **Baseline level of each indicator (where available) and targeted level of the indicator by 2022 (where defined)**
- **Stakeholders who are responsible for collecting or ensuring access to data for measuring each indicator**
4. THE HEALTH SECTOR M&E SYSTEM CAPACITY

4.1. Introduction

The UNAIDS (2008) Organising Framework for a Functional National HIV Monitoring and Evaluation System identifies 12 components of an operational M&E system. The M&E plan is but one of the essential components of a good M&E system. The 12 components of a functional M&E system are the following: (1) organisational structure; (2) human capacity; (3) partnerships and coordination; (4) M&E plan; (5) a costed M&E workplan; (6) advocacy, communications, and culture; (7) routine programme monitoring; (8) surveys and surveillance; (9) databases; (10) supportive supervision and auditing; (11) evaluation and research; and (12) data dissemination and use.

The 12 components can be organised operationally into three categories. The first category, comprising components 1–6, relates to people, partnerships, and planning that support data production and use, which constitute the enabling environment for M&E to function. The second category is concerned with systems for collecting, capturing, and verifying data, and transforming data into useful information (components 7–11), whereas the last component addresses the central purpose of M&E, which is analysis of data to create information that in turn is disseminated to inform and empower decision making at all levels. Figure 4 presents the 12 components framework.
4.2. **Health Sector M&E System Strengthening Activities**

In 2015, NACP assessed its M&E system using the 12 components framework. This assessment provided specific recommendations on activities for strengthening the NACP M&E system. This section presents recommended activities for selected components that will be implemented during the term of the HSHSP IV. These activities have been updated to reflect current needs. Activities related to data collection, management, and dissemination and use are discussed in a later chapter.

1. **Organisational structure for M&E**
   - Fill all M&E posts within NACP’s national and subnational structures
   - Advocate with the President’s Office-Public Services Management (PO-PSM) and President’s Office-Regional Administration and Local Government (PO-RALG) to finalise a scheme of service for council-level M&E officers to improve health sector HIV/AIDS services data collection, quality, and use
• Strengthen the capacity of council and regional HMIS focal persons on HIV data systems, including in District Health Information System-Version 2 (DHIS 2) data analysis, visualisation, and presentation
• Strengthen collaboration with implementing partners in the implementation of M&E activities for the health sector HIV response
• Promote and strengthen regional M&E technical working groups (TWGs) as a forum for reviewing performance against the HSHSP IV indicators and addressing data quality and use challenges

2. Human capacity
• Assess knowledge and skills amongst regional and council-level HIV/AIDS M&E focal persons, and develop a capacity-building plan as appropriate
• Promote the use of the training system monitoring and reporting tool (TrainSMART) in tracking all HIV M&E training activities
• Review the curriculum for medical records and determine any scope for adding health sector HIV and M&E contents

3. Partnerships
• Strengthen the NACP national health sector HIV M&E subcommittee as a platform for engaging with stakeholders
• Develop a regular (quarterly) newsletter as a tool for stakeholder engagement
• Participate actively in the Ministry of Health, Community Development, Gender, Elderly and Children (MOHCDGEC) M&E Strengthening Initiative (MESI) and TWG

4. Routine programme monitoring
• Develop data collection tools and data management guidelines for condom distribution; information education, and communication (IEC); and key populations (KP) programmes
• Establish and strengthen monitoring and reporting of financial resources and investments for both the government and implementing partners for the health sector HIV response

5. Surveys and surveillance
• Conduct demonstration studies to determine the operational and implementation strategies required to roll out pre-exposure prophylaxis (PrEP) and HIV self-testing interventions amongst different populations in Tanzania
• Conduct IBBSS every two years as per protocol
• Conduct workplace intervention surveys

6. National and subnational databases
• Complete the integration of HIV care and treatment data reporting into the DHIS 2
• Harmonise import and export functionalities of all existing HIV databases (CTC2, home-based care [HBC], HIV testing and counselling [HTC], STI, prevention of mother-to-child transmission [PMTCT])
• Develop a database for the KP programme

7. Evaluation and research
• Develop an inventory of HIV/AIDS research and evaluation
• Develop a health sector HIV research and evaluation agenda
• Develop and disseminate policy briefs on major completed research studies

The national health sector M&E system-strengthening plan based on the activities identified above is provided in Appendix 3.
5. HEALTH SECTOR M&E DATA COLLECTION STRATEGY

5.1. Introduction

A functional monitoring and evaluation system requires standard monitoring indicators and standards for collecting, analysing, and reporting data. This chapter includes information on how data for tracking the implementation of HSHSP IV will be collected, reported, and shared to facilitate decision making.

Two broad types of data sources will be used: routine data sources (for monitoring data) and nonroutine data sources (for evaluation data). Monitoring data will be collected on inputs and outputs, using standard programme-based data collection tools. Evaluation data, on the other hand, will be collected on outcomes and impacts, primarily through population-based biological, behavioural, and social surveys and surveillance.

5.2. Routine Data Sources

Routine data sources will facilitate tracking of activities as they are implemented. Routine monitoring data will be collected at health facilities by healthcare providers with the support of implementing partners, using standardized tools. Table 4 summarizes different standard tools for collecting monitoring data, and the responsibility for and frequency of their reporting.

<table>
<thead>
<tr>
<th>Data collection standard tools</th>
<th>Stakeholder to complete</th>
<th>Reporting frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 HIV testing and counselling tools</td>
<td>Healthcare providers</td>
<td>Monthly</td>
</tr>
<tr>
<td>2 HIV care and treatment tools</td>
<td>Healthcare providers</td>
<td>Quarterly</td>
</tr>
<tr>
<td>3 HIV home-based care tools</td>
<td>HBC providers and coordinators</td>
<td>Monthly</td>
</tr>
<tr>
<td>4 Sexually transmitted infections tools</td>
<td>Healthcare providers</td>
<td>Monthly</td>
</tr>
<tr>
<td>5 Prevention of mother-to-child transmission of HIV tools</td>
<td>Healthcare providers</td>
<td>Quarterly/monthly</td>
</tr>
<tr>
<td>7 Voluntary male medical circumcision (VMMC)</td>
<td>Healthcare providers</td>
<td>Monthly reports</td>
</tr>
<tr>
<td>8 Key populations</td>
<td>Healthcare providers</td>
<td>Monthly reports</td>
</tr>
</tbody>
</table>

Examples of routine data sources are as follows:

**Care and treatment reports:** The care and treatment programme unit within NACP produces monthly programme data that will be used to respond to some of the indicators in the M&E plan. The data will include cohort analysis of clients on ART. These data will enable reporting on clients that are on treatment 12 months after its initiating. Even though the reports are prepared on a routine basis, NACP will conduct the analysis quarterly and periodically provide results required for purposes of the M&E plan. The analysis will also assess adherence to and provide proxy data on drug resistance.

**Health Management Information System (HMIS) reports:** The HMIS is the main source of health facility (public and private) service delivery data under the health sector. It generates routine integrated reports for the health sector and provides the bulk of data for monitoring the HSHSP IV.
The DHIS 2 is now the primary national health service data electronic reporting platform. Data collected on health facility- and community-based services are compiled at the facility level and entered into the DHIS 2 on a monthly basis. The DHIS 2 allows the aggregation of national and subnational level data. It will be the primary source of data for the HSHSP IV M&E plan. All data submitted through this system will be verified and approved by NACP before publication.

**National Blood Transfusion Services (NBTS) Reports:** These reports are produced by the NBTS annually.

**Programmatic reports:** These reports include, for example, the PMTCT, ART, and National TB and Leprosy Programme reports, produced on a quarterly basis by the respective programmes, which provide additional data not captured under the HMIS/DHIS 2.

### 5.3. Nonroutine Data Sources (Evaluation Data)

NACP will collect evaluation data in collaboration with other stakeholders. The major data collection initiatives for measuring the impact of the health sector HIV response include THIS and TDHS.

**Tanzania HIV Impact Surveys (THIS):** The THIS survey collects data related to HIV knowledge and behaviour, and HIV prevalence amongst women and men ages 15–49. The latest THIS survey, conducted in Tanzania in 2016–2017, provides data on HIV viral load and incidence. The surveys are conducted under the leadership of the National Bureau of Statistics (NBS). The previous survey, including malaria indicators, was conducted in 2012. It is anticipated that a follow-up THIS study will be conducted by the end of the HSHSP IV.

**Tanzania Demographic and Health Survey (TDHS):** The TDHS is conducted every five years as part of a worldwide Demographic Health Surveys (DHS) programme funded by the U.S. Agency for International Development (USAID). The DHS programme assists countries in the collection of data to monitor and evaluate population, health, and nutrition programmes. The last DHS was conducted in 2015–2016. A follow-on survey is anticipated within the timeframe of the HSHSP IV.

**Tanzania Service Provision Assessment (TSPA):** The TSPA survey is a health facility assessment that provides a comprehensive overview of the status of health service delivery. It collects information on the overall availability of different facility-based health services. Two rounds of TSPA have been conducted in Tanzania—the first one in 2006 and the second in 2014–2015. Like the THIS and TDHS, the TSPA is conducted through the leadership of the NBS. It is expected that the next round of the TSPA will occur within the term of the HSHSP IV.

**Epidemic modelling:** NACP will also continue to use the Estimation and Projection Package and Spectrum AIDS Impact Model developed by WHO and UNAIDS to monitor changes in HIV outcomes. Spectrum modelling is based on routinely collected data, such as adult and child treatment coverage, PMTCT, and sentinel surveillance data.

**ANC-PMTCT data utility surveys:** These surveys are conducted biannually at ANC sentinel surveillance sites.

**Key populations surveys:** These surveys will be conducted for identified KPs as relevant to the Tanzanian context. There has been a general paucity of studies on KPs in Tanzania, but it is expected that new studies will occur during the life of the HSHSP IV.

**Special studies:** Other special studies will be commissioned as deemed necessary to respond to specific indicators not adequately addressed by the other surveys. The HSHSP IV specifically
recommends demonstration studies to determine the operational and implementation strategies required to roll out PrEP and HIV self-testing interventions amongst different populations in Tanzania.

Figure 5 highlights the interface between monitoring and evaluation data within the health sector M&E system.

**Figure 5. Health sector HIV and AIDS M&E system**
5.4. Reporting and Data Flow

The primary source of routine data for the health sector HIV response is the health facility. There are additional services provided at the community level, such as HBC and community outreaches. Patient- and client-level data collected at the health facility and community levels are used to generate monthly and quarterly summary reports, which are submitted to the District Medical Officer’s (DMO’s) office. The district then aggregates the summary reports from the various health facilities through the DHIS 2. The aggregated data entered at the district level are accessible to stakeholders at all levels, from the regions to the national level, through the DHIS 2.

In 2017, the MOHCDGEC started rolling out direct entry of data into the DHIS 2 by health facilities, starting with hospitals and ultimately covering all health facilities, to improve both data quality and use at the point of collection. The quality of data from one level to another will be ensured through NACP’s existing data management guidelines. Figure 6 illustrates the reporting, data flow, and feedback process, as well as timelines.

Figure 6. Reporting timeline, data flow, and feedback mechanism

5.5. **Data Management**

Data management includes procedures and standards for handling data, ensuring data quality, and storing data during programme implementation. The data management process includes data sourcing, collection, collation and aggregation, analysis, reporting and use. Procedures identified in the NACP’s *National Guideline for the Management of HIV and AIDS Data Quality* (2012) and the MOHCDGEC’s *National Guidelines for Health Data Quality Assessment* (2016) will be followed throughout the data management process.

5.5.1. **Data Recording and Checking**

Both paper-based and electronic systems will be used at the facility level to collect patient- and client-level data during service delivery. A data entry supervisor will perform data checks daily, report any errors, and promptly make corrections with the support of the facility in-charge. The facility in-charge will compile monthly reports and share them with the facility management team before submission to the District AIDS Control Coordinator and DMO. At the district level, reports aggregated from all health facilities will be reviewed by the CHMT before entry into the DHIS 2. Aggregated data will be entered into the DHIS 2 monthly and reports produced quarterly.

5.5.2. **Data Retention**

A data retention protocol allows programme implementers to store data for a certain period as back-up in case of any loss, for data quality audit purposes, accountability to the government or donors, or use in further analysis. The existing MOHCDGEC data recording and retention policy for government data will be used to document, maintain, and retain HIV/AIDS data at all levels.

5.5.3. **Data Storage and Confidentiality**

Each data reporting level will ensure appropriate storage, maintenance, and security for archiving their electronic and paper-based records. Confidentiality of patient-level data will be ensured through a password-protected electronic archival and back-up system for electronic data, and storage in a locked area for paper-based data.

5.6. **Data Quality Assurance**

Crucial to the successful performance of the M&E system is the quality of the data it generates. In line with the NACP’s *National Guideline for the Management of HIV and AIDS Data Quality* (2012) and the MOHCDGEC’s *National Guidelines for Health Data Quality Assessment* (2016), data quality assurance will be performed periodically to verify reported data, identify strengths or gaps in the systems supporting data collection, build M&E capacity, and address challenges found at each level for overall improvement of data quality. NACP will ensure at least one annual data quality assessment, covering national, regional, district, facility, and community levels. The data quality assessment will cover all components of data management and include at least one indicator per programme.

At the regional level, each RHMT will be required to perform a minimum of two data quality assessments (DQAs) per year in every district, involving at least one facility per district. Each assessment at the district level will include a minimum of one indicator per intervention area.

At the district level, DQAs will be integrated into quarterly supervision visits. It is recommended that a DQA be performed at least twice per year for every facility and include at least one indicator per intervention delivered at that facility.
6. **STAKEHOLDER ROLES AND RESPONSIBILITIES**

Implementation of the health sector HIV and AIDS M&E plan is under the management and supervision of the Directorate of Preventive Services in the MOHCDGEC through the NACP. However, the involvement of other stakeholders from both the public and private sectors is critical to successful implementation of the M&E plan.

M&E functions will be implemented at three main levels: national, regional, and council/district. The NACP will be directly responsible for implementation of the plan at the national level. The RHMT and CHMT will be responsible for implementation at the regional and council/district levels, respectively. The roles and responsibilities of different stakeholders in the implementation of the M&E plan are specified below.

6.1. **Ministry of Health, Community Development, Gender, Elderly and Children (MOHCDGEC)** provides overall technical leadership guidance, advice, and M&E on the implementation of HSHSP IV

- Facilitates effective development, recruitment, and deployment of skilled health workers at health facilities in collaboration with the PO-RALG, PO-PSM, and Ministry of Finance
- Ensures availability of a harmonised and integrated HMIS
- Ensures adherence to guidelines, standards, and regulations
- Promotes and oversees operational research on health sector HIV prevention, care and treatment, and support services
- Ensures timely submission of reports, as well as proper storage and documentation of records
- Provides relevant feedback and dissemination of data and strategic information to all stakeholders involved in HIV/AIDS interventions
- Ensures integration of data quality activities into routine supervision at all levels
- Conducts a data quality assessment at least once a year to assess the status of the data collected and reported at different levels
- Ensures that regional and district levels conduct DQAs at least twice per year

6.2. **National AIDS Control Programme (NACP)**

- Coordinates and oversees the implementation and monitoring and evaluation of health sector HIV prevention, care, treatment, and support services
- Designs and develops an M&E framework, and ensures the availability of recording and reporting tools for the HSHSP IV
- Facilitates the integration of an HIV information system within the national M&E strengthening initiative and strengthens and promotes effective and efficient data collection, analysis, and use of HIV/AIDS information at all levels
- Organises and coordinates health sector HIV prevention, care, treatment, and supports operational research in collaboration with research institutions
• Leads the implementation of operational research on health sector HIV prevention, care, treatment, and support services

6.3. **Research and Academic Institutions**

• Plan and conduct research studies and disseminate findings to key stakeholders in the country as part of improving the health sector HIV prevention, care, treatment, and support services

• Jointly coordinate synthesis of new knowledge from research and support the MOHCDGEC/NACP in translating research findings into policy and practice

• Support the MOHCDGEC/NACP scale-up of proven interventions and best practices through the development of appropriate tools and methodologies

• Establish, maintain, use, or make available research and surveillance platforms for the evaluation of national HIV/AIDS interventions to the MOHCDGEC/NACP

6.4. **President’s Office-Regional Administration and Local Government (PO-RALG)**

• Facilitates effective recruitment and deployment of skilled health workers at health facilities in collaboration with the MOHCDGEC and PO-PSM; collaborates with various stakeholders for planning and implementation of health sector HIV prevention, care, treatment, and support services

• Designs and develops planning guidelines to facilitate the implementation of health sector HIV prevention, care, treatment, and support services, such as the Medium-Term Expenditure Framework

6.5. **Regional Health Management Teams (RHMTs)**

• Provide technical support to CHMTs to incorporate and implement health sector interventions for HIV prevention, care, and treatment in their annual comprehensive council health plans (CCHPs)

• Coordinate, supervise, monitor, and evaluate health sector HIV prevention, care, treatment, and support services provided by both governmental and nongovernmental institutions in the region

• Ensure availability and adherence to national guidelines and standards for health sector HIV prevention, care, treatment, and support services

• Support CHMTs to collect, compile, analyse, interpret, and disseminate data on health sector HIV/AIDS services

• Receive, compile, analyse, use, and disseminate health sector HIV prevention, care, treatment, and support services data from the councils and send them to the national level

• Ensure coordinated implementation of and compliance with national M&E guidelines, standard operating procedures (SOPs), and protocols

• Provide technical assistance to districts in implementing data quality initiatives
- Collect reports from all districts in all programme areas and verify reported numbers before aggregating them to produce a regional report
- Provide feedback to districts according to the guidelines
- Aggregate district-level data (paper or electronic) into regional reports on a monthly or quarterly basis, depending on the agreed-upon timeline
- Ensure timely submission of reports to the MOHCDGEC and NACP
- Ensure linkage between implementing partners, districts, health facilities, and other stakeholders
- Plan and implement capacity-building activities at the district and facility levels to ensure sustainable training of healthcare providers on data quality activities
- Integrate data quality assessments into quarterly supervision visits to districts and facilities
- Conduct at least two data quality assessments per year, covering the regional, district, facility, and community levels
- Support districts to conduct DQAs in accordance with national guidelines

6.6. **Council Health Management Teams (CHMTs)**

- Plan and incorporate HSHSP IV activities into the CCHP
- Strengthen the HMIS by compiling, disseminating, and using health sector HIV prevention, care, treatment, and support data for service improvement
- Ensure that reports are received from all facilities in all programme areas and verify reported numbers before aggregating them to produce a district report
- Stamp all reports to show when they were received and ensure that the data are entered into the appropriate database
- Aggregate facility-level data (paper or electronic) to produce district reports (monthly/quarterly) according to the agreed-upon timeline; the reports must be signed by the designated CHMT member
- Provide relevant feedback to health facilities on the findings of DQAs and ways to improve in weak areas
- Ensure that training and mentorship for service providers are routinely conducted
- Ensure that facilities have cabinets for storage of data collection and reporting tools, including patient files
- Develop an annual data quality plan for the district
- Enforce the implementation of data quality activities in the health facilities
- Ensure that healthcare providers involved in data collection and reporting are trained on data quality
- Integrate data quality assessments into routine supportive supervision
- Ensure that DQAs are conducted at least twice per year for each facility
6.7. **Health Facilities (Hospitals, Health Centres and Dispensaries)**

- Ensure the collection, analysis, use, and dissemination of data for improved service delivery
- Ensure the availability of data collection and reporting tools
- Ensure the completeness of all variables in the data collection and reporting tools
- Verify the accuracy and reliability of the recorded and reported data
- Ensure the availability of all SOPs and guidelines on how to fill out data collection, as well as reporting tools, and that they are used accordingly
- Produce facility (monthly and quarterly) reports and ensure their timely submission to the district
- Ensure that analysis and summarisation of data and reports are done properly
- Ensure the availability of cabinets for storage of files, reports, and all data related to HIV/AIDS, as well as a proper filing system that uses appropriate registration numbers to simplify storage and retrieval of documents
- Ensure that staff involved in data recording and reporting are trained on the data quality guidelines
- Implement data quality activities in all sections of the health facility where data are being collected and reported

6.8. **Communities**

- Collect data on community-based HIV services, such as HBC
- Maintain records of all services provided, using standard reporting tools
- Submit activity reports regularly (monthly and quarterly) to the nearest health facility as guided

6.9. **Implementing Partners**

- Support the MOHCDGEC in formulating national guidelines and SOPs related to M&E activities
- Collaborate with the MOHCDGEC in ensuring the sustainable availability of recording and reporting tools
- Collaborate with the MOHCDGEC in conducting supportive supervision visits to the RHMTs and CHMTs
- Provide support to the regions and councils covered to conduct DQAs and improve systems for data collection and reporting
- Collaborate with regional and district teams in training, supportive supervision, and mentoring of healthcare workers on data quality activities
- Support the CHMTs to ensure proper verification and completeness of the data recorded at the facility level
- Support the CHMTs/RHMTs in submitting all reports in a timely manner
• Assist in capacity building for data analysis, use, and dissemination at the regional, district, facility, and community levels
7. DATA DISSEMINATION AND USE

Data collected through this M&E plan will need to be analysed and packaged appropriately for different audiences to facilitate their use in planning, resources allocation, programme decision making, and assessment of progress against targets set for the health sector HIV and AIDS response. This chapter describes some key barriers to data use and activities to be undertaken to facilitate data analysis, dissemination, and use at different levels.

7.1. Barriers to Data Use

There are several barriers to data use, including a lack of motivation to review and use data because of excessive workload and a lack of feedback on performance; lack of staff commitment also is a key barrier, especially at the service delivery point. There is a perception amongst healthcare workers that data use initiatives create an additional burden rather than help improve job performance. However, recognition of data use as an important task and dissemination of success stories on data use by national, regional, and district health management authorities can help alleviate such motivational barriers.

Limited capacity to analyse, interpret, and communicate data, not only at the health facility level, but even at the national, regional, and district levels, is also practical barrier to data use. Continuous capacity building on the use of the DHIS 2’s capabilities for data analysis, augmented with skills in data synthesis and packaging for different audiences, is needed to improve data use.

Finally, data use may be hindered by infrastructural factors, such as a shortage of data reporting tools, parallel data collection systems that are not always accessible, lack of Internet connectivity, and data storage systems that do not ensure consistent data quality. The integration of data collection and reporting processes would help improve the infrastructure for data use.

7.2. Data Analysis

Since 2015, the reporting of HIV/AIDS programmes has been integrated into the DHIS 2. This integration is expected to improve access to data and promote data analysis from the health facility to district, regional, and national levels. Health facilities that can now input data directly into the DHIS 2 will conduct monthly and quarterly analysis of their data under the guidance of the CHMTs. The CHMTs will organise quarterly data analysis and validation meetings, during which they will look at overall reporting rates, report submission timeliness, data quality, and performance against key indicators. The RHMTs will organise similar meetings to review the performance of all districts within the region. At the national level, NACP will organise annual data analysis workshops that draw together subnational health management teams and implementing partners to analyse data and develop reports on the status of the health sector HIV/AIDS response.

The data analysis activities will be organised to coincide with key decision-making moments at different levels. Key decision-making moments include the following:

- HIV/AIDS M&E quarterly meetings (national level)
- NACP strategic review meetings (national level)
- NACP quarterly M&E subcommittee meetings (national level)
- NACP biannual data review meetings
- RHMTs’, CHMTs’, and implementing partners’ quarterly meetings (regional/council level)
- Weekly performance review meetings (health facility level)
• Quarterly multisectoral AIDS committee meetings (council level)

The information products from the data analysis will include the following:

Health facility level
Monthly and quarterly reports

District level
Quarterly reports

National level
• Quarterly programme monitoring reports
• Annual HIV/AIDS reports
• Quarterly bulletins
• International reports: biennial UNGASS Report, PEPFAR annual reports, UNAIDS Global AIDS Response Reporting (GARP) report, Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) annual reports

7.3. Data Dissemination and Use

NACP will organise M&E results dissemination meetings at the national, regional, and district levels with implementing partners, communities, and health facilities on a quarterly and biannual basis. The dissemination of the M&E results will serve the following purposes:

• Provide feedback to various implementers on the efforts being made and achievements
• Share and use the data and information for better targeting and planning of HIV/AIDS interventions at the district level
• Provide feedback on efforts and resource use in the health sector HIV/AIDS response, and articulate lessons learned, gaps, and challenges faced at the subnational and national levels
• Enhance networking and harmonisation of data use efforts

The types of feedback approaches to promote data use will include the following:

• Making performance comparisons amongst regions, districts, and facilities
• Making recommendations on how to improve performance
• Disseminating exemplary best practices
• Recognizing good performance
• Focusing on resources or helping to find resources
• Directing feedback to those with authority to make decisions
• Linking routine to nonroutine data for a comprehensive view of performance
• Identifying, strengthening, and promoting data use champions at all levels

Table 5 summarises the dissemination plan for different information products arising from the M&E plan.
Table 5. Dissemination plan for informational products from the HSHSP IV M&E plan

<table>
<thead>
<tr>
<th>Product</th>
<th>Frequency/timeline</th>
<th>Responsible</th>
<th>Contents</th>
<th>Audience</th>
<th>Dissemination format</th>
</tr>
</thead>
<tbody>
<tr>
<td>Programme monitoring report</td>
<td>Quarterly</td>
<td>NACP</td>
<td>Progress on programme monitoring indicators</td>
<td>Programme manager</td>
<td>Summary, reports</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Politicians and government officials</td>
<td>Policy briefs, brochures</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Implementing partners</td>
<td>Fact sheets, visual presentations, dissemination workshops</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Regions and districts</td>
<td>Fact sheets, visual presentations, dissemination workshops</td>
</tr>
<tr>
<td>HIV and AIDS report</td>
<td>Annual</td>
<td>NACP</td>
<td>Progress on programme monitoring indicators</td>
<td>Programme manager</td>
<td>Summary, reports</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Politicians and government officials</td>
<td>Policy briefs, brochures</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Implementing partners</td>
<td>Fact sheets, visual presentations, dissemination workshops</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Regions and districts</td>
<td>Fact sheets, visual presentations, dissemination workshops</td>
</tr>
<tr>
<td>Bulletin</td>
<td>Quarterly</td>
<td>NACP</td>
<td>Service provision data update</td>
<td>Public</td>
<td>NACP website</td>
</tr>
<tr>
<td>UNGASS report</td>
<td>Biennial</td>
<td>NACP</td>
<td></td>
<td>Donors/funders</td>
<td>Full reports</td>
</tr>
<tr>
<td>PEPFAR reports</td>
<td>Annual</td>
<td>NACP</td>
<td></td>
<td>Donors/funders</td>
<td>Full reports</td>
</tr>
<tr>
<td>GFATM reports</td>
<td>Annual</td>
<td>NACP</td>
<td></td>
<td>Donors/funders</td>
<td>Full reports</td>
</tr>
<tr>
<td>HIV/AIDS and STI surveillance reports</td>
<td></td>
<td>NACP</td>
<td>Survey results</td>
<td>Donors/funders</td>
<td>Full reports, NACP website</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Politicians and government officials</td>
<td>policy briefs, brochures, NACP website</td>
</tr>
<tr>
<td>Product</td>
<td>Frequency/timeline</td>
<td>Responsible</td>
<td>Contents</td>
<td>Audience</td>
<td>Dissemination format</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>--------------------</td>
<td>-------------</td>
<td>-------------------------------</td>
<td>---------------------------</td>
<td>------------------------------------------</td>
</tr>
<tr>
<td>ANC report</td>
<td></td>
<td>NACP</td>
<td>Survey results</td>
<td>Donors/funders</td>
<td>Full reports, NACP website</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Politicians and government officials</td>
<td>policy briefs, brochures, NACP website</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Regions and districts</td>
<td>Fact sheets, visual presentations, NACP website</td>
</tr>
<tr>
<td>Care and treatment report</td>
<td>Annual</td>
<td>NACP</td>
<td></td>
<td>Government and implementing partners</td>
<td>Full reports, NACP website</td>
</tr>
<tr>
<td>National HIV drug resistance report</td>
<td>Annual</td>
<td>NACP</td>
<td></td>
<td>Government and implementing partners</td>
<td>Full reports, NACP website</td>
</tr>
<tr>
<td>PMTCT report</td>
<td>Annual</td>
<td>NACP</td>
<td></td>
<td>Government and implementing partners</td>
<td>Full reports, NACP website</td>
</tr>
<tr>
<td>SPECTRUM estimation and projection report</td>
<td></td>
<td>NACP</td>
<td></td>
<td>Government and implementing partners</td>
<td>Full reports, NACP website</td>
</tr>
<tr>
<td>District-level reports</td>
<td>Quarterly</td>
<td>CHMT</td>
<td>Service provision data update</td>
<td>District implementing partners, health workers</td>
<td>Fact sheets, visual presentation</td>
</tr>
<tr>
<td>Health facility-level reports</td>
<td>Monthly and quarterly</td>
<td>Healthcare providers</td>
<td>Service provision data update</td>
<td>Health facility staff, community</td>
<td>Fact sheets, visual presentation</td>
</tr>
</tbody>
</table>
7.4. **Capacity Building**

In addition to tailored feedback and analysis, continuous capacity building will be conducted to enable key decision makers from the health facility to national levels to independently synthesise, analyse, and interpret data for programming. The large number of staff in need of capacity building, as well as staff turnover, requires a continuous capacity-building approach. Two key capacity-building approaches will be pursued to improve data analysis and use during implementation of the HSHSP IV. The first approach will be an expansion of the DHIS 2 training curriculum to include data analysis, visualisation, and presentation; the second will be the expansion of the number of supportive supervision visits provided by programme and M&E staff at all levels of the health system.

Examples of staff to be targeted for the capacity-building activities include the following:

- NACP data managers
- Regional/council health secretaries
- Regional/council HMIS focal persons
- Regional/council medical recorders
- Regional/council health management teams
8. MONITORING AND EVALUATION OF HEALTH SECTOR HIV PLAN IMPLEMENTATION

The HSHSP IV M&E plan identifies indicators (Appendix 1) against which programme performance will be assessed. These indicators will be tracked regularly to ensure that programme targets are met and the implementation of the strategic plan is on course.

8.1. Annual M&E Operational Plans

To ensure effective implementation of the M&E plan, NACP will develop annual M&E operational plans with active stakeholder involvement, based on M&E system strengthening and other data quality and data use interventions. The operational plans will be more detailed to provide the expected number of participants in different activities, timelines, and associated costs. The implementation status of the operational plans will be reviewed at the end of every year at the Joint Annual Programme Review (JAPR) meetings, along with data collected on the different indicators identified in the M&E plan. The JAPR will bring together the NACP, MOHCDGEC, PO-RALG, RHMTs/CHMTs, implementing partners, and other stakeholders.

In addition to the JAPR, the health sector HIV M&E subcommittee and the MOHCDGEC’s MESI and TWG meetings will provide a critical forum for reviewing progress of the implementation of the HSHSP IV and promptly instituting any necessary corrective measures.

8.2. Mid- and End-Term Evaluation

Two evaluations will also be conducted to determine the success of the HSHSP IV. NACP will organise a joint mid-term review (MTR) before the end of the third year of the HSHSP IV. This assessment will focus on progress made in implementing the plan and the appropriateness of the overall strategic direction. The evaluation will be designed to inform the remaining period of the plan and recommend adjustments where needed.

The NACP will facilitate an independent external evaluation in the final year of the HSHSP IV (end-term evaluation), focusing on achievements (impacts and outcomes) of the HSHSP IV. The end-term evaluation will also provide contextual information for the subsequent planning period.

Both evaluations will be conducted with significant involvement of stakeholders. The costs for the evaluations will be included in the health sector budget. When appropriate, the MTR and the end-of-term evaluation will be combined with the JAPR for that year.

8.3. Assumptions for the Successful Implementation of the HSHSP IV M&E Plan

The successful implementation of this M&E plan hinges on the assumption that the NACP will rally all key stakeholders to implement the strategic activities identified in the HSHSP IV. Stakeholders will commit to an annual work planning process whereby programme performance targets will be set and responsibility for their attainment defined, including financial contributions. Another assumption is that implementing partners will harmonise their support for M&E-related activities based on NACP’s annual M&E operational plan. A budgetary provision of 7–10 percent of the total cost of implementing the strategic activities in the HSHSP IV will be set aside for M&E-related activities.
REFERENCES


## APPENDIX 1. SUMMARY OF HSSSP IV INDICATORS, BY LEVEL, IN THE M&E RESULTS PATHWAY (IMPACT, OUTCOME, AND OUTPUT)

<table>
<thead>
<tr>
<th>Indicator reference number</th>
<th>Indicator</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>STRATEGIC AREA 1: HIV TESTING SERVICES</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Strategic outcome 1: 90% of people living with HIV are aware of their status by 2022</strong></td>
<td></td>
</tr>
<tr>
<td>1.1</td>
<td>Proportion of women and men ages 15+ years who have ever tested for HIV and know their results</td>
<td>Outcome</td>
</tr>
<tr>
<td>1.2</td>
<td>Proportion of individuals who test for HIV as couples</td>
<td>Output</td>
</tr>
<tr>
<td>1.3*</td>
<td>Percentage of young people ages 15-24 years who are living with HIV</td>
<td>Impact</td>
</tr>
<tr>
<td></td>
<td><strong>Intervention area 1.1: Linkage to HIV prevention, care, treatment, and support services</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Strategic outcome 2: All people (100%) identified as HIV positive during community and facility HTS are linked to HIV care, treatment, and support services by 2022</strong></td>
<td></td>
</tr>
<tr>
<td>1.4</td>
<td>Proportion of individuals (all ages, including children) diagnosed with HIV and linked to appropriate services</td>
<td>Outcome</td>
</tr>
<tr>
<td></td>
<td><strong>STRATEGIC AREA 2: PREVENTION OF NEW HIV INFECTIONS</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Intervention area 2.1: Comprehensive condom programming</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Strategic outcome 1: 85% of women and men engaged in multiple sexual partnerships report use of a condom at last sexual intercourse</strong></td>
<td></td>
</tr>
<tr>
<td>2.1</td>
<td>Percentage of women and men ages 15+ who had higher-risk sex in the last 12 months who reported using a condom the last time they had sexual intercourse</td>
<td>Outcome</td>
</tr>
<tr>
<td>2.2*</td>
<td>Percentage of members of KVPs who reported using a condom during their last high-risk sexual encounter</td>
<td>Outcome</td>
</tr>
<tr>
<td></td>
<td><strong>Intervention area 2.2: Programming for key and vulnerable populations (KVPs)</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Strategic outcome 2: Increased access and use of HIV services by KVP</strong></td>
<td></td>
</tr>
<tr>
<td>2.3</td>
<td>Proportion of health facilities providing KVP-friendly services</td>
<td>Output</td>
</tr>
<tr>
<td>2.4</td>
<td>Number of KVP receiving HIV services</td>
<td>Output</td>
</tr>
<tr>
<td>2.5</td>
<td>Percentage of members of KVPs who have been tested for HIV in the last 12 months and know their results</td>
<td>Outcome</td>
</tr>
<tr>
<td>2.6</td>
<td>Percentage of KVP who are HIV infected</td>
<td>Outcome</td>
</tr>
<tr>
<td></td>
<td><strong>Intervention area 2.3: Voluntary male medical circumcision (VMMC)</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Strategic outcome 3: 90% male circumcision rate attained by all regions by 2022</strong></td>
<td></td>
</tr>
<tr>
<td>2.7</td>
<td>Proportion of males receiving VMMC services at healthcare facilities in the last 12 months</td>
<td>Output</td>
</tr>
<tr>
<td>2.8</td>
<td>Number of circumcised clients experiencing at least one moderate or severe adverse event (AE) during or following surgery within the reporting period</td>
<td>Outcome</td>
</tr>
<tr>
<td></td>
<td><strong>Intervention area 2.4: STI management</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Strategic outcome 4: Incidence of STIs in the general population and syphilis amongst pregnant women reduced by 50% respectively by 2022</strong></td>
<td></td>
</tr>
<tr>
<td>2.9</td>
<td>Prevalence of syphilis amongst pregnant women</td>
<td>Outcome</td>
</tr>
<tr>
<td>Indicator reference number</td>
<td>Indicator</td>
<td>Level</td>
</tr>
<tr>
<td>----------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>--------</td>
</tr>
<tr>
<td>2.10</td>
<td>Percentage of antenatal care attendees screened for syphilis at first antenatal care visit</td>
<td>Output</td>
</tr>
<tr>
<td>2.11</td>
<td>Percentage of ANC care attendees screened for syphilis</td>
<td>Output</td>
</tr>
</tbody>
</table>

**Intervention area 2.5: Blood safety**

**Strategic outcome 5:** All (100%) donated blood units will be screened for TTI (HIV, HBV, HCV, and syphilis) as per the WHO quality assurance procedure by 2022

2.12 Percentage of donated blood units screened for HIV per WHO quality assurance procedures | Outcome |

**Intervention area 2.6: Reproductive health cancers**

**Strategic outcome 6:** By 2022, 60% of female clients ages 30–50 screened for cervical cancer using VIA and cryotherapy

2.13 Percentage of HIV-positive women ages 15–49 screened for cervical cancer using the VIA method | Output |

2.14 Proportion of health facilities providing cervical cancer screening (VIA) | Output |

2.15 Proportion of health facilities using cryotherapy/loop electrosurgical excision procedure (LEEP) for early treatment of precancerous cervical lesions | Output |

**Strategic area 3: Facility-based care and support for PLHIV**

**Intervention area 3.1: ART services for adults**

**Strategic outcome 1:** By 2022, 95% of all adults (>15) diagnosed with HIV will be on ART

3.1* Number of AIDS-related deaths per 100,000 population | Impact |

3.2 Number of PLHIV newly initiated on treatment in the past 12 months | Output |

3.3 Number of PLHIV currently on ART | Output |

3.4 Percentage of persons on second-line regimen during reporting period | Outcome |

3.5* Percentage of adults and children with HIV known to be on treatment 12 months after initiation of ART | Outcome |

3.6 Percentage PLHIV on ART monitored using viral load as a standard of care | Output |

3.7* Number and percentage of people living with HIV and on ART who are virologically suppressed (amongst all those currently on treatment who received a viral load measurement regardless of when they started ART) | Outcome |

**Intervention area 3.2: Paediatric ART services**

**Strategic outcome 2:** All children under 15 years initiated and 90% retained on ART by 2022

3.8* Estimated percentage of child HIV infections from HIV-positive women delivering in the past 12 months | Impact |

3.9 Percentage of HIV-exposed infants receiving a virological test for HIV within 2 months of birth | Outcome |

3.10 Percentage of HIV-exposed infants tested with DNA-polymerase chain reaction (PCR) within 2 months of age | Output |

3.11 Percentage of dried blood spot (DBS) samples rejected at DNA-PCR testing laboratories | Output |
<table>
<thead>
<tr>
<th>Indicator reference number</th>
<th>Indicator</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.12</td>
<td>Percentage of DBS tests that have turnaround time for DBS reduced to less than 4 weeks from when the sample is collected to results back to client/caregiver</td>
<td>Output</td>
</tr>
</tbody>
</table>

**Intervention area 3.3: ART for pregnant and lactating women**

**Strategic outcome 3:** Reduction of mother-to-child transmission of HIV from an estimated 8% in 2015 to 4% at the end of breastfeeding by 2022

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.13</td>
<td>Proportion of pregnant women tested for HIV and who know their status</td>
</tr>
<tr>
<td>3.14</td>
<td>Proportion of male partners of pregnant mothers tested for HIV and who know their HIV status</td>
</tr>
<tr>
<td>3.15*</td>
<td>Percentage of HIV-infected pregnant women receiving ARVs to reduce the risk of MTCT of HIV</td>
</tr>
<tr>
<td>3.16</td>
<td>Proportion of women alive and on ART during PMTCT care</td>
</tr>
</tbody>
</table>

**Intervention area 3.4: HIV co-infections and co-morbidities**

**Strategic outcome 4:** By 2022, the burden of other HIV co-infections and co-morbidities amongst PLHIV reduced by 50 percent of the 2016 level

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.17</td>
<td>Number of HIV-positive patients who received TB treatment</td>
</tr>
<tr>
<td>3.18</td>
<td>Percentage of HIV-positive patients starting isoniazid preventive therapy (IPT) during the reporting period</td>
</tr>
</tbody>
</table>

**Intervention area 3.5: Achieving viral suppression**

**Strategic outcome 5:** By 2022, 95% of all PLHIV who are on ART achieve viral suppression

Refer to indicators 3.6 and 3.7

**Intervention area 3.6: Community-based HIV/AIDS care**

**Strategic outcome 6:** Improved identification, retention, adherence, and psychosocial support to PLHIV through community-based HIV and AIDS services

**Strategic outcome 7:** Improved identification, retention, adherence, and psychosocial support to PLHIV

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.19</td>
<td>Percentage of PLHIV on care and treatment enrolled in community-based health services (CBHS)</td>
</tr>
<tr>
<td>3.20</td>
<td>Percentage of missed appointment/lost to follow-up (LTFU) clients followed up and linked back to health facility services by community-based HIV and AIDS service providers</td>
</tr>
<tr>
<td>3.21</td>
<td>Percentage of care and treatment facilities with a designated CBHS provider/supervisor</td>
</tr>
</tbody>
</table>

**STRATEGIC AREA 4: BUILDING RESILIENT AND SUSTAINABLE SYSTEMS FOR HEALTH TO SUPPORT THE NATIONAL RESPONSE**

**Intervention area 4.1: Quality improvement of HIV and AIDS services**

**Strategic outcome 1:** RHMTs, CHMTs, and health facilities have active QI teams that oversee the implementation, documentation, and reporting of quantitative data on the quality of HIV and AIDS services

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1</td>
<td>Percentage of health facilities (hospitals) with active quality improvement (QI) teams, i.e., completing at least 1 QI cycle per intervention per quarter</td>
</tr>
<tr>
<td>4.2</td>
<td>Percentage of RHMTs and CHMTs with active QI teams</td>
</tr>
<tr>
<td>4.3</td>
<td>Proportion of health facilities providing quality HIV testing and counselling services according to national standards</td>
</tr>
<tr>
<td>Indicator reference number</td>
<td>Indicator</td>
</tr>
<tr>
<td>----------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>4.4</td>
<td>Percentage of health facilities providing HIV services assessed for data quality in the last 12 months</td>
</tr>
</tbody>
</table>

**Intervention area 4.2: Medicine and technologies**

**Strategic outcome 2: Uninterrupted supply of medicines and commodities for STI/RTI, HIV, and AIDS at all levels by 2022**

| 4.5                        | Percentage of health facilities that have experienced a stockout of selected tracer items in the HIV programme in the last 3 months (HSHSP III, p. 81) | Output |
| 4.6                        | Proportion of Government of Tanzania (GOT) expenditure from its own funds on procurement of ARVs, HIV rapid test kits, and diagnostics | Output |
| 4.7                        | Proportion of hospitals and health centres implementing an electronic logistics data management system | Output |
| 4.8                        | Proportion of health facilities with at least one clinical staff trained on rational use of HIV medicines and pharmacovigilance | Output |

**Intervention area 4.3: Health facility commodity management and rational use of medicine**

**Strategic outcome 3: Commodity management and logistical information will be generated and used at different levels of the health delivery system to improve decision making**

| 4.9                        | Percentage of HIV care and treatment facilities prescribing and dispensing ARV/opportunistic infections (OIs) medicines according to national guidelines | Output |
| 4.10                       | Percentage of ordering facilities submitting ARV/OIs and laboratory logistics reports within a specified time limit | Output |

**Strategic outcome 4: Improved tracking of adverse drug effects**

| 4.11                       | Number of care and treatment facilities documenting adverse drug reactions (ADRs) and reporting them to the Tanzania Food and Drug Authority (TFDA) | Output |
| 4.12                       | Proportion of health facilities using pharmacovigilance reports at a facility level | Output |

**Intervention area 4.4: Laboratory services**

**Strategic outcome 5: Quality laboratory services provided for HIV/AIDS clients at all levels**

| 4.13                       | Percentage of care and treatment hospital and health centre laboratories enrolled in the Strengthening of Laboratory Management towards Accreditation (SLMTA) process according to the WHO/Regional Office for Africa (AFRO) Stepwise Laboratory Improvement Process towards Accreditation (SLIPTA) quality assurance standards | Output |
| 4.14                       | Percentage of hospital and health centre laboratories enrolled in the SLMTA process that achieved star rank according to the WHO/AFRO (SLIPTA) quality assurance standards | Output |
| 4.15                       | Percentage of health facilities offering ART (CTC and PMCTC that provide viral load and early infant diagnosis (EID) testing services through conventional and point-of-care testing | Output |
| 4.16                       | Percentage of EID and HIV viral load (HVL) tests conducted at care and treatment laboratories against the annual targets | Output |
| 4.17                       | Percentage of care and treatment laboratories that submit Laboratory Information System (LIS) reports (HVL, EID, CD4, | Output |
Intervention area 4.5: Healthcare equipment maintenance (laboratory equipment)

Strategic outcome 6: Uninterrupted HIV services as a result of timely PPM of laboratory and other healthcare equipment

- 4.18 Percentage of laboratory equipment covered by PPM system
- 4.19 Percentage of equipment at care and treatment facilities/laboratories reported as broken down in a given period
- 4.20 Percentage of average time the laboratory equipment at care and treatment facilities/laboratories are functioning per quarter against the minimal requirement

Intervention area 4.6: HIV strategic information

Strategic outcome 7: A well-regulated, monitored, and evaluated programme with up-to-date research outcomes relevant for HIV and AIDS that addresses improved data quality and informs programme performance

- 4.21 Proportion of RHMTs/CHMTs with a government employee designated to perform M&E functions
- 4.22 Percentage of facilities providing HIV services with timely submission of reports into the DHIS 2
- 4.23 Percentage of health facilities providing ART services with electronic data management systems (CTC database)

Intervention area 4.8: Community-based health system

Strategic outcome 8: Strengthened community participation for quality community-based health services (CBHS)

- 4.24 Percentage of PLHIV on care and treatment enrolled in CBHS
- 4.25 Percentage of missed appointment/loss to follow-up (LTFU) clients followed up and linked back to health facility services by community-based HIV and AIDS services providers
- 4.26 Percentage of care and treatment facilities with a designated CBHS provider/supervisor

STRATEGIC AREA 5: CROSS-SECTOR HIV AND AIDS INTERVENTIONS AND OTHER INNOVATIVE INVESTMENTS

Intervention area 5.1: Stigma, discrimination, and gender-based violence (GBV)

Strategic outcome 1: Proportion of PLHIV who reported experiencing stigma and discrimination from healthcare providers reduced from 40% to zero by 2022

- 5.1 Percentage of women and men ages 15+ expressing specific accepting attitudes towards people with HIV and AIDS
- 5.2 Percentage of PLHIV who experienced or perceived stigma when accessing health services

Intervention area 5.2: Targeted social and behaviour change communication (SBCC)

Strategic outcome 2: Adoption of safer sexual practices

Strategic outcome 3: Increased uptake of comprehensive HIV and AIDS prevention, treatment, care, and support services

- 5.3 Percentage of women and men ages 15–24 who correctly identify both ways of preventing the sexual transmission of HIV and reject major misconceptions about HIV transmission
- 5.4 Percentage of young women and men ages 15–24 who have had sexual intercourse before the age of 15
<table>
<thead>
<tr>
<th>Indicator reference number</th>
<th>Indicator</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention area 5.3: Health sector workplace interventions</td>
<td>Strategic outcome 4: Increased access to comprehensive workplace interventions focusing on HIV, TB, and HBV prevention, care, and support services by employees</td>
<td></td>
</tr>
<tr>
<td>5.5</td>
<td>Number of health sector institutions implementing workplace HIV interventions</td>
<td>Output</td>
</tr>
</tbody>
</table>
| Intervention area 5.4: Adolescents and young people | Strategic outcome 5: Reduction of new HIV infections amongst adolescents and young women by 50% by 2022  
Strategic outcome 6: 95 percent of adolescents living with HIV will be on ART by 2022 | |
| 5.6 | Percentage of adolescents and youth who receive HTS and receive their test results | Output |
| Intervention area 5.5: Male involvement | Strategic outcome 7: Improved male involvement in HIV prevention, care, treatment, and support for their own health and the health of their partners and families | |
| Refer to indicator 1.2: Proportion of individuals who test for HIV as couples | |
| Refer indicator 3.14: Proportion of male partners of pregnant mothers tested for HIV and who know their HIV status | |
| Intervention area 5.6: Gender-based violence | Strategic outcome 8: Reduce HIV associated sexual and gender-based violence  
Strategic outcome 9: Mitigate effects of GBV on survivors, especially women and young people | |
| 5.7 | Proportion of men and women ages 15–49 who experienced physical or sexual violence in the past 12 months | Outcome |
| 5.8 | Proportion of sexually abused clients receiving HIV post-exposure prophylaxis | Outcome |
| 5.9 | Proportion of sexually and physically abused clients tested for HIV | Output |

Note: Core HSHSP IV indicators are marked with an asterisk (1.3, 2.2, 3.1, 3.5, 3.7, 3.8, and 3.15).
## APPENDIX 2 COMPREHENSIVE HSHSP IV INDICATORS MATRIX

<table>
<thead>
<tr>
<th>No</th>
<th>Indicator</th>
<th>Indicator definition (numerator and denominator)</th>
<th>Disaggregation</th>
<th>Indicator source</th>
<th>Data source</th>
<th>Frequency</th>
<th>Baseline</th>
<th>Target</th>
<th>Stakeholder</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Strategic Area 1: HIV Testing Services</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Strategic outcome 1: 90% of people living with HIV are aware of their status by 2022</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| T1 | Proportion of women and men ages 15+ years who have ever been tested for HIV and know their results | **Numerator:** Number of women and men ages 15+ years who have ever been tested for HIV and know their results  
**Denominator:** Number of women and men ages 15+ | Age, sex, residence, marital status, wealth quantile, education | UNGASS, GARP | IHS 2016/17 | Every 5 yrs | Women = 70.8% Men = 59.2% (IHS 2016-17) | Women = 90% Men = 90% | TACADS, NBS, MOHCD, GEC, PORALG |
| T2 | Proportion of individuals who test for HIV as couples | **Numerator:** Number of individuals who received testing and counselling services for HIV, and received their results as couples  
**Denominator:** Total number of individuals who received testing and counselling services during the same period | Age, sex | PEPFAR Next Generation Indicator (NGI) P11.1.D | NACP Annual Surveillance Report | Annually | 4% (2016) general population | 7% | NACP |
| T3 | Percentage of young people ages 15-24 tested whose HIV test results are positive | **Numerator:** Number of young people ages 15-24 tested whose HIV test results are positive  
**Denominator:** Number of young people ages 15-24 tested for HIV | Age: 15-19/20-24 Region Sex | Tanzania HIV/AIDS and Malaria Indicator Survey (THMIS) | 4-5 yrs | 12% (2016) | To be decided (TBD) | TACADS, NBS |
**Intervention area 1.1: Linkage to HIV prevention, care, treatment, and support services**

**Strategic outcome 2:** All (100%) people identified as HIV positive during community and facility HIS are linked to HIV care, treatment, and support services by 2022

<table>
<thead>
<tr>
<th>No</th>
<th>Indicator</th>
<th>Indicator definition (numerator and denominator)</th>
<th>Disaggregation</th>
<th>Indicator source</th>
<th>Data source</th>
<th>Frequency</th>
<th>Baseline</th>
<th>Target</th>
<th>Stakeholder</th>
</tr>
</thead>
</table>
| 1.4 | Proportion of individuals (all ages, including children) diagnosed with HIV and linked to appropriate services | **Numerator:** Number of individuals (adults and children) who were tested for HIV, given results, and linked to appropriate services  
**Denominator:** Number of individuals (adults and children) who tested positive for HIV | All ages, sex  
Geographic location | HSHP IV | NACP, HIS | 5 yrs and annually | 91% (HIS 2016/17), 98% programme data 2017 | 100% | NACP, NBS |

**STRATEGIC AREA 2: Prevention of new HIV Infections**

**Intervention area 2.1: Comprehensive condom programming**

**Strategic outcome 1:** 85 percent of women and men engaged in multiple sexual partnerships report use of a condom at last sexual intercourse

<table>
<thead>
<tr>
<th>No</th>
<th>Indicator</th>
<th>Indicator definition (numerator and denominator)</th>
<th>Disaggregation</th>
<th>Indicator source</th>
<th>Data source</th>
<th>Frequency</th>
<th>Baseline</th>
<th>Target</th>
</tr>
</thead>
</table>
| 2.1 | Percentage of women and men ages 15+ who had higher-risk sex in the last 12 months who reported using a condom the last time they had sexual intercourse | **Numerator:** Number of women and men ages 15+ who had higher-risk sex (non-marital, non-cohabiting partner) in the last 12 months who reported using a condom the last time they had sexual intercourse  
**Denominator:** Number of all respondents ages 15–49 who reported having had more than one sexual partner in the last 12 months | Age, sex  
CARP, GF M&E toolkit | HIS (adolescent/youth secondary analysis) | Every 4-5 yrs | Males: 35%  
Females: 27% (HIS 2016/17) | Males: 40%  
Females: 32%  
2021 | TACADS/ NACP, IPs, TAMISEMI-ARYA |
| 22 | Percentage of members of KVPs | **Numerator:** Number of members of KVPs who | Age | UNGASS | Every 2-3 yrs | PSW=50%  
MSM=95%  
MMS=50% | TACADS/ NACP, IPs, TAMISEMI-ARYA |
<table>
<thead>
<tr>
<th>No</th>
<th>Indicator</th>
<th>Indicator definition (numerator and denominator)</th>
<th>Disaggregation</th>
<th>Indicator source</th>
<th>Data source</th>
<th>Frequency</th>
<th>Baseline</th>
<th>Target</th>
<th>Stakeholder</th>
</tr>
</thead>
<tbody>
<tr>
<td>23</td>
<td>Propportion of health facilities providing KVP- friendly services</td>
<td>Numerator: Number of health facilities providing KVP- friendly services</td>
<td>by facility type, geographic area</td>
<td>HSHSP IV 2017-2022</td>
<td>Health facility survey (SPA)</td>
<td>Every 2 yrs</td>
<td>NONE</td>
<td>TBD</td>
<td>TACALS/NACP, IPS, TAMISEMI-APYA</td>
</tr>
<tr>
<td>24</td>
<td>Number of KVP receiving HIV services</td>
<td>Numerator: Number of KVP receiving HIV services</td>
<td>KVP type: SW, PWD, PWUD, AGYW, MSM; type of service (HTS, ART)</td>
<td>HSHSP IV 2017-2022</td>
<td>Health facility survey (SPA)</td>
<td>Every 2 yrs</td>
<td>SW, 25.35; PWD, 3.61; PWUD, 9.5; AGYW, 16.9%; MSM, 3.29</td>
<td>TBD</td>
<td>TACALS/NACP</td>
</tr>
<tr>
<td>25</td>
<td>Percentage of members of KVPs who have tested for HIV in the last 12 months</td>
<td>Numerator: Number of KVP who have been tested for HIV during the last 12 months and know their results</td>
<td>By KVP age range, type: SW, PWD, PWUD, AGYW, MSM</td>
<td>UNAIDS: GARP, HSHSP IV 2017-2022</td>
<td>IBSSS</td>
<td>Periodic, every 2 yrs</td>
<td>FSW, 76.4% (2017); MSM, 78.3% (2017)</td>
<td>100%</td>
<td>MORDEL; GECE/NACP, IPS, TAMISEMI-APYA</td>
</tr>
</tbody>
</table>
## Indicator Definition (numerator and denominator)

### No indicator

#### Numerator
Number of KVP respondents

#### Denominator
Number of KVP who tested for HIV

### Indicators

#### Numerator
Number of KVP who are HIV-positive

#### Denominator
Number of KVP who are HIV-positive

### Age, Sex

#### Numerator
Age, sex

#### Denominator
KVP type: sex, worker, PWD, PWL, AGYW, MSM

### GARP 2013; GFEM&E toolkit

#### Source
NACP consensus report 2014

### Frequency
3-5 yrs

### Baseline
PWD: 71.5% (2017)

### Target

### Stakeholder
MOLEDGEC/NAACP/IPs, TAMSEMI-AYA

### Intervention area 2.3: Voluntary male medical circumcision (VMMC)

### Strategic outcome 3: Ninety percent (90%) male circumcision rate attained by all regions by 2022

#### Numerator
Number of males receiving VMMC services at healthcare facilities in the last 12 months

#### Denominator
Total males targeted for VMMC

### Age

#### Numerator
Age

#### Denominator
SSHP IV 2017-2022, PEPFAR, monitoring, evaluation, and reporting (MER) 2D

### DHS 2

#### Frequency
Monthly, quarterly, annually

### Baseline
27%

### Target
90%

### Stakeholder
NAACP/IPs, TAMSEMI-AYA, DPS

#### Numerator
Number of circumcised clients experiencing at least one moderate or severe adverse event (AE) during or following surgery within the reporting period

#### Denominator
Number of clients circumcised that experience one or more moderate or severe AE(s) during the reporting period

### Monitoring and Evaluation Plan

#### Frequency
Monthly, quarterly, annually

### Baseline
0.6%

### Target
<0.5%

### Stakeholder
NAACP/IPs, TAMSEMI
### Intervention area 2.4: STI management

**Strategic outcome 4:** Incidence of STIs in the general population and syphilis amongst pregnant women reduced by 50% respectively by 2022

<table>
<thead>
<tr>
<th>No</th>
<th>Indicator</th>
<th>Indicator definition (numerator and denominator)</th>
<th>Disaggregation</th>
<th>Indicator source</th>
<th>Data source</th>
<th>Frequency</th>
<th>Baseline</th>
<th>Target</th>
<th>Stakeholder</th>
</tr>
</thead>
</table>
| 2.9 | Prevalence of syphilis amongst pregnant women | **Numerator:** Number of ANC attendees tested positive for syphilis  
**Denominator:** Number of ANC attendees tested for syphilis | Age | GAR; HSHSP IV | Sentinel surveillance | Every 2 yrs | 18% | 1% | MOHCDGC/NACP, IPs, TAMSEM-AYA |
| 2.10 | Percentage of ANC attendees screened for syphilis at first ANC visit | **Numerator:** Number of ANC attendees screened for syphilis at first ANC visit  
**Denominator:** Number of ANC attendees at first ANC visit | Age | GAR; HSHSP IV | Sentinel surveillance | Every 2 yrs | 50% | 100% | MOHCDGC/NACP, IPs, TAMSEM-AYA |
| 2.11 | Percentage of ANC attendees screened for syphilis | **Numerator:** Number of ANC attendees treated for syphilis  
**Denominator:** Number of ANC attendees with a positive syphilis serology | Age | GAR; HSHSP IV | Routine data | Monthly, quarterly | 70% | 100% | MOHCDGC/NACP, TAMSEM-AYA |

### Intervention area 2.5: Blood safety

**Strategic outcome 5:** All (100%) donated blood units will be screened for TTI (HIV, HBV, HCV, and syphilis) as per the WHO quality assurance procedure by 2022

<table>
<thead>
<tr>
<th>No</th>
<th>Indicator</th>
<th>Indicator definition (numerator and denominator)</th>
<th>Disaggregation</th>
<th>Indicator source</th>
<th>Data source</th>
<th>Frequency</th>
<th>Baseline</th>
<th>Target</th>
<th>Stakeholder</th>
</tr>
</thead>
</table>
| 2.12 | Percentage of donated blood units screened for HIV per WHO quality assurance procedures | **Numerator:** Number of units of donated blood screened for HIV per WHO quality assurance procedures  
**Denominator:** Number of all blood units donated | None | NMS/HSHSP IV | NBIS | Quarterly, annually | 6% | 100% | MOHCDGC/NBIS |
### Intervention area 2.6: Reproductive health cancers

<table>
<thead>
<tr>
<th>No</th>
<th>Indicator</th>
<th>Indicator definition (numerator and denominator)</th>
<th>Disaggregation</th>
<th>Indicator source</th>
<th>Data source</th>
<th>Frequency</th>
<th>Baseline</th>
<th>Target</th>
<th>Stakeholder</th>
</tr>
</thead>
</table>
| 2.13 | Percentage of HIV-positive women ages 15-49 screened for cervical cancer using VIA method | **Numerator:** Number of HIV-positive women ages 15-49 screened for cervical cancer using VIA method  
**Denominator:** Number of HIV-positive women ages 15-49 currently on care | Age, geographic location | WHO | DHS 2 | Quarterly, annually | 22% | 30% | MOH/DOGE, IPs, TA/SEMII-AFYA |
| 2.14 | Proportion of health facilities providing cervical cancer screening (VIA) | **Numerator:** Number of health facilities providing VIA for cervical cancer screening  
**Denominator:** Number of health facilities that provide HIV care and treatment services | Facility type (hospital, health centre, dispensary), ownership (public, private, faith-based organisation (FBO)), geographic location | WHO | DHS 2 | Quarterly, annually | 435/629 (67%) | 80% | MOH/DOGE, IPs, TA/SEMII-AFYA |
| 2.15 | Proportion of health facilities using cryotherapy/LEEP for early treatment of precancerous cervical lesions | **Numerator:** Number of health facilities using cryotherapy/LEEP for early treatment of precancerous cervical lesions  
**Denominator:** Number of designated health facilities that provide HIV care and treatment services | Facility type (hospital, health centre, dispensary), ownership (public, private, FBO), geographic location | WHO/ Programme guideline 2015 | Programme report | Annually | TBD | 80% | MOH/DOGE, IPs, TA/SEMII-AFYA |
<table>
<thead>
<tr>
<th>No</th>
<th>Indicator</th>
<th>Indicator definition (numerator and denominator)</th>
<th>Disaggregation</th>
<th>Indicator source</th>
<th>Data source</th>
<th>Frequency</th>
<th>Baseline</th>
<th>Target</th>
<th>Stakeholder</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.1</td>
<td>Number of AIDS-related deaths per 100,000 population</td>
<td>Number of AIDS-related deaths per 100,000 population</td>
<td>Female vs. male age range: 15-19, 20-24, and 25+ years, region</td>
<td>HSHSP IV 2017-2022</td>
<td></td>
<td>49.1</td>
<td>23.1</td>
<td></td>
<td>IACADS/NBS</td>
</tr>
<tr>
<td>3.2</td>
<td>Number of PLHIV newly initiated on treatment in the past 12 months</td>
<td>Number of adults and children newly initiated on ART in the past 12 months</td>
<td>Sex, age, pregnancy status, breastfeeding</td>
<td>HSHSP IV</td>
<td>DHIS 2</td>
<td>Quarterly, annually</td>
<td>244,780</td>
<td>186,492</td>
<td>MOLDD/GEC/NACP, IPS, DPs</td>
</tr>
<tr>
<td>3.3</td>
<td>Number of PLHIV currently on ART</td>
<td>Number of PLHIV currently on ART</td>
<td>Sex, age, pregnancy status, breastfeeding</td>
<td>HSHSP IV</td>
<td>DHIS 2</td>
<td>Quarterly, annually</td>
<td>964,812</td>
<td>1,273,820</td>
<td>MOLDD/GEC/NACP, IPS, DPs</td>
</tr>
</tbody>
</table>
| 3.4| Percentage of persons who are on second-line regimen during reporting period | **Numerator:** Number of persons who are on second-line regimen during reporting period  
**Denominator:** Total number of persons currently on ART during reporting period | Age, sex | HSHSP IV | DHIS 2       | Quarterly, annually | 29%    | 10%       | MOLDD/GEC/NACP, IPS, DPs |

**Strategic area 3: Facility-based care and support for PLHIV**

**Intervention area 3.1: ART services for adults**

**Strategic outcome 1:** By 2022, 95 percent of all adults (>15) diagnosed with HIV will be on ART
<table>
<thead>
<tr>
<th>No</th>
<th>Indicator</th>
<th>Indicator definition (numerator and denominator)</th>
<th>Disaggregation</th>
<th>Indicator source</th>
<th>Data source</th>
<th>Frequency</th>
<th>Baseline</th>
<th>Target</th>
<th>Stakeholder</th>
</tr>
</thead>
</table>
| 3.5 | Percentage of adults and children with HIV known to be on an ART treatment 12 months after initiation of ART | **Numerator:** Number of adult and children who are still alive and on ART at 12 months after initiating treatment  
**Denominator:** Total number of adults who initiated ART who were expected to achieve 12-month outcomes within the reporting period, including those who have died since starting ART, those who have stopped ART, and those recorded as LTFU at month 12 | Female vs. male  
Age range: 15-19, 20-24, and 25+ years  
Region | HSHSP IV 2017-2022 | Care and treatment report cohort analysis | Annually | Adults: 82%  
Children: 86% (2017) | 90% for both (adults & children) | MOHCDGEC/NACP, IPS, DPs |
| 3.6 | Percentage of PLHIV on ART monitored using VL as a standard of care | **Numerator:** Number of clients on ART monitored using VL as a standard of care  
**Denominator:** Total number of clients currently on ART | Age, sex | HSHSP IV 2017-2022 | WHO, CIC2 database, HIS 2 | Quarterly, annually | 75% (2017) | 95% | MOHCDGEC/NACP, IPS, DPs |
| 3.7 | Number and percentage of people living with HIV and on ART who are virologically suppressed (amongst all those currently on treatment who received a VL measurement regardless of when they started ART) | **Numerator:** Number of people living with HIV and on ART who have a suppressed VL (<1,000 copies/mL)  
**Population-level denominator:** Number of people living with HIV who are currently receiving ART | Age <5, 5-9, 10-14, 15-19, 20-24, 25-49, 50+, sex, geographic location | WHO/  
Guideline, 2015, p. 153 | ART register, patient records, population-based surveys; e.g., DHS | Semi-annually and annually | 85% (2017) | 100% | MOHCDGEC/NACP, IPS, DPs |
<table>
<thead>
<tr>
<th>No</th>
<th>Indicator</th>
<th>Indicator definition <em>(numerator and denominator)</em></th>
<th>Disaggregation</th>
<th>Indicator source</th>
<th>Data source</th>
<th>Frequency</th>
<th>Baseline</th>
<th>Target</th>
<th>Stakeholder</th>
</tr>
</thead>
</table>
| 38 | Estimated percentage of child HIV infections from HIV-positive women delivering in the past 12 months | **Numerator:** Estimated number of children who will be newly infected with HIV due to MTCT amongst children born to HIV-positive women  
**Denominator:** Estimated number of HIV-positive women who delivered in the previous 12 months | None | HSP IV 2017-2022 | Spectrum modelling | Annually | 1.9% (2016) | 1.3% | MOHCDGC |
| 39 | Percentage of HIV-exposed infants receiving a virological test for HIV within 2 months of birth | **Numerator:** Number of HIV-exposed infants tested with DNA/PCR within 2 months of birth  
**Denominator:** Estimated number of all infants born to HIV-infected mothers | None | HSP IV 2017-2022 | Numerator; programme data  
Denominator; Spectrum estimates | Annually | 55.2% (2016) | 90% (2022) | MOHCDGC/PMICT |
| 3.10 | Percentage of HIV-exposed infants tested with DNA/PCR within 2 months of birth | **Numerator:** Number of HIV-exposed infants who are tested with DNA/PCR within 2 months of birth  
**Denominator:** Number of all infants born to HIV-infected mothers | Infants who received DNA-PCR test in first 2 months after birth and 2-12 months; infants tested should be counted only once | NMSP | PMICL programme data | Annually | 55.2% (2016) | 90% (2022) | None |
### Indicator definition (numerator and denominator)

- **Numerator**: Number of DBS samples rejected at DNA-PCR testing laboratories.
- **Denominator**: Number of all DBS samples received at DNA-PCR testing laboratories.

### Disaggregation

- None

### Indicator source

- HSHP III

### Data source

- Lab data

### Frequency

- Annually

### Baseline

- 3% National HIV Laboratory Quality Assurance and Training Centre (NHLQATC)

### Target

- <1%

### Stakeholder

- MOHCGEC NHLQATC

### Percentage of DBS samples rejected at DNA-PCR testing laboratories

#### No 3.11

#### Indicator

Percentage of DBS samples rejected at DNA-PCR testing laboratories

#### Numerator

Number of DBS samples rejected at DNA-PCR testing laboratories

#### Denominator

Number of all DBS samples received at DNA-PCR testing laboratories

#### Disaggregation

None

#### Indicator source

HSHP III

#### Data source

Lab data

#### Frequency

Annually

#### Baseline

3% National HIV Laboratory Quality Assurance and Training Centre (NHLQATC)

#### Target

<1%

#### Stakeholder

MOHCGEC NHLQATC

### Percentage of DBS tests that have turnaround time for DBS reduced to less than 4 weeks from when the sample is collected to results back to client or caregiver

#### No 3.12

#### Indicator

Percentage of DBS tests that have turnaround time for DBS reduced to less than 4 weeks from when the sample is collected to results back to client or caregiver

#### Numerator

Number of DBS tests that have turnaround time for DBS reduced to less than 4 weeks from when the sample is collected to results back to client or caregiver

#### Denominator

Number of all DBS tests

#### Disaggregation

None

#### Indicator source

HSHP III

#### Data source

Facilities with CTC2 database; enhanced monitoring

#### Frequency

Annually

#### Baseline

60 days

#### Target

28 days

#### Stakeholder

MOHCGEC PMTCT

### Intervention area 3.3: ART for pregnant and lactating women

#### Strategic outcome 3: Reduction of MTCT of HIV from an estimated 8% in 2015 to 4% at the end of breastfeeding by 2022

#### No 3.13

#### Indicator

Proportion of pregnant women tested for HIV and know their status

#### Numerator

Number of pregnant women tested for HIV and given results

#### Denominator

Estimated number of pregnant women in a year

#### Age (16-19, 20-24, ≥25)

Age (16-19, 20-24, ≥25)

#### Frequency

Annually

#### Baseline

91%

#### Target

98%

#### Stakeholder

MOHCGEC PMTCT

### HSHSP IV Monitoring and Evaluation Plan

67
<table>
<thead>
<tr>
<th>No</th>
<th>Indicator</th>
<th>Indicator definition (numerator and denominator)</th>
<th>Disaggregation</th>
<th>Indicator source</th>
<th>Data source</th>
<th>Frequency</th>
<th>Baseline</th>
<th>Target</th>
<th>Stakeholder</th>
</tr>
</thead>
</table>
| 3.14 | Proportion of male partners of pregnant mothers tested for HIV and know their HIV status | **Numerator**: Number of male partners of pregnant women tested for HIV and given results  
**Denominator**: Estimated number of pregnant women per year | None | eMICHI | Routine PMICT data (MHS) | Annually | 57.2% | 80% | MOH/EC/PMICI |
| 3.15 | Percentage of HIV-infected pregnant women receiving ARVs to reduce the risk of MTCT of HIV | **Numerator**: Number of HIV-positive pregnant women who received ARVs during the past 12 months to reduce risk of MTCT  
**Denominator**: Estimated number of HIV-positive pregnant women identified in the last 12 months, based on ANC surveillance  
By regimen type:  
(1) Single dose nevirapine only  
(2) Prophylactic regimens using a combination of 2 ARVs  
(3) Prophylactic regimens using a combination of 3 ARVs  
(4) ART for HIV-positive pregnant women eligible for treatment | By regimen type | HSPF IV 2017-2022 | PMICT database | Annually | TBD | 95% | MOH/EC/NACP, RCH clinics |
| 3.16 | Proportion of women alive and on ART during PMICT care | **Numerator**: Number of mothers alive and on ART while in PMICT care  
**Denominator**: All mothers tested as HIV positive in a specified time | 12 months, 24 months | eMICHI | Routine PMICT cohort data | Annually | Not available | >95% at 12 months, >90% at 24 months | MOH/EC/PMICI |
<table>
<thead>
<tr>
<th>No</th>
<th>Indicator</th>
<th>Indicator definition (numerator and denominator)</th>
<th>Disaggregation</th>
<th>Indicator source</th>
<th>Data source</th>
<th>Frequency</th>
<th>Baseline</th>
<th>Target</th>
<th>Stakeholder</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.17</td>
<td>Number of HIV-positive patients who received TB treatment</td>
<td>Number of HIV-positive patients who received TB treatment</td>
<td>Age, sex</td>
<td>DHS 2</td>
<td>Annually</td>
<td>14,343 (2017)</td>
<td>63,691</td>
<td>NACP, National Tuberculosis and Leprosy Programme (NTLP), IPs, TAMIS-AYA</td>
<td></td>
</tr>
<tr>
<td>3.18</td>
<td>Percentage of HIV-positive patients starting IPT during the reporting period</td>
<td>Numerator: Number of HIV-positive patients starting IPT Denominator: Number of adults and children enrolled in HIV care during the reporting period</td>
<td>Age, sex</td>
<td>DHS 2, CIC2 database</td>
<td>Quarter, annually</td>
<td>74%</td>
<td>100%</td>
<td>NACP, NTLP, IPs, TAMIS-AYA</td>
<td></td>
</tr>
</tbody>
</table>

**Strategic outcome 5:** By 2022, 95 percent of all PLHIV who are on ART achieve viral suppression

**Strategic outcome 6:** Improved identification, retention, adherence, and psychosocial support to PLHIV through community-based HIV and AIDS services

**Strategic outcome 7:** Improved identification, retention, adherence, and psychosocial support to PLHIV
<table>
<thead>
<tr>
<th>No</th>
<th>Indicator</th>
<th>Indicator definition (numerator and denominator)</th>
<th>Disaggregation</th>
<th>Indicator source</th>
<th>Data source</th>
<th>Frequency</th>
<th>Baseline</th>
<th>Target</th>
<th>Stakeholder</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><strong>Denominator</strong>: Total number of PLHIV receiving care and treatment services</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.20</td>
<td>Percentage of missed appointment/LTFU clients followed up and linked back to health facility services by CBHS</td>
<td><strong>Numerator</strong>: Number of missed appointments/LTFU clients linked back to health facility services by CBHS providers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.21</td>
<td>Percentage of care and treatment facilities with a designated CBHS provider or supervisor</td>
<td><strong>Numerator</strong>: Number of care and treatment facilities with a designated CBHS provider/supervisor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**STRATEGIC AREA: 4 Building resilient and sustainable systems for health to support the national response**

**Intervention area 4.1: Quality improvement of HIV and AIDS services**

**Strategic outcome 1: RHMTs, CHMTs, and health facilities have active quality improvement teams that oversee the implementation, documentation, and reporting of quantitative data on the quality of HIV and AIDS services**

| 4.1 | Percentage of health facilities (hospitals) with active QI teams, i.e., completing at least 1 | **Numerator**: Number of health facilities providing HIV services with an active QI team | Facility type (dispensary, health centre, | PHSP III | HIV routine programme data | Quarterly | No | 50% | NACP |

<p>|                |                                           |                                      | PHSP III                     | HIV routine programme data | Quarterly | No | 50% | NACP |</p>
<table>
<thead>
<tr>
<th>No</th>
<th>Indicator</th>
<th>Indicator definition (numerator and denominator)</th>
<th>Disaggregation</th>
<th>Indicator source</th>
<th>Data source</th>
<th>Frequency</th>
<th>Baseline</th>
<th>Target</th>
<th>Stakeholder</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>QI cycle per intervention per quarter</td>
<td><strong>Denominator:</strong> Number of health facilities providing HIV services <strong>Numerator:</strong> Number of health facilities providing HIV services</td>
<td>hospital) and by residence</td>
<td>None</td>
<td>HSHP III</td>
<td>Annually</td>
<td>No</td>
<td>90%</td>
<td>NACP</td>
</tr>
<tr>
<td>4.2</td>
<td>Percentage of RHMs and CHMs with active QI teams</td>
<td><strong>Numerator:</strong> Number of RHMs/CHMs with active QI team <strong>Denominator:</strong> Number of RHMs/CHMs</td>
<td>None</td>
<td>HSHP III</td>
<td>Routine Programme data</td>
<td>Biannually</td>
<td>81% (2014-2015)</td>
<td>100%</td>
<td>NACP</td>
</tr>
<tr>
<td>4.3</td>
<td>Percentage of health facilities providing quality HIV testing and counselling services according to national standards</td>
<td><strong>Numerator:</strong> Number of facilities providing quality HIV testing and counselling services according to national standards <strong>Denominator:</strong> Total number of facilities providing HIV testing and counselling services</td>
<td>Disaggregated by facility type (dispensary, health centre, hospital), facility ownership (public or private), and residence (rural vs urban)</td>
<td>HSHP III</td>
<td>ISPA</td>
<td>Biannually</td>
<td>26 (100%)</td>
<td>100%</td>
<td>MOHCDGEc</td>
</tr>
<tr>
<td>4.4</td>
<td>Percentage of health facilities providing HIV services assessed for data quality in the last 12 months</td>
<td><strong>Numerator:</strong> Number of health facilities providing HIV services assessed for data quality in the last 12 months <strong>Denominator:</strong> Total number of health facilities providing HIV services</td>
<td>By intervention type (care and treatment, etc.) and facility level</td>
<td>HSHP III</td>
<td>NACP/DQA report/CHIS</td>
<td>Annually</td>
<td>Care and treatment: 26 (100%) Pediatric: 14 (100%) Other interventions: 26 (100%)</td>
<td>100%</td>
<td>MOHCDGEc</td>
</tr>
</tbody>
</table>

**Intervention area 4.2: Medicine and technologies**

**Strategic outcome 2: Uninterrupted supply of medicines and commodities for STI/RTI, HIV, and AIDS at all levels by 2022**
<table>
<thead>
<tr>
<th>No</th>
<th>Indicator</th>
<th>Indicator definition (numerator and denominator)</th>
<th>Disaggregation</th>
<th>Indicator source</th>
<th>Data source</th>
<th>Frequency</th>
<th>Baseline</th>
<th>Target</th>
<th>Stakeholder</th>
</tr>
</thead>
</table>
| 4.5 | Percentage of health facilities that have experienced stockouts of selected tracer items in HIV programme in the last 3 months (HSHSP III, p. 81) | **Numerator:** Number of health facilities that have experienced stockouts of at least one tracer item in the last 12 months  
**Denominator:** Number of health facilities providing care and treatment | Disaggregated by facility type (dispensary, health centre, hospital), facility ownership (public, private, NGO), geographic location | G&RM&E Toolkit; NV&F | HMIS | Quarterly | 5% | 3% | MOHCDGEC |
| 4.6 | Proportion of Government of Tanzania expenditure from own funds on procurement of ARVs, HIV rapid test kits, and diagnostics | **Numerator:** Amount of funds allocated for procurement of ARVs, HIV rapid test kits, and diagnostics  
**Denominator:** Total expenditure for HIV commodities | None | Newmester GF (2018-2020) | FBR (Public Expenditure Review), NASA (National AIDS Spending Assessment) | Biennially | 12 billion | 14.4 billion | TACADS |
| 4.7 | Proportion of hospitals and health centres implementing electronic logistics data management system | **Numerator:** Number of hospital and health centres implementing logistics data management system  
**Denominator:** Number of hospitals and health centres implementing HIV care and treatment services | By facility type (hospital, health centre), geographic location | LMIS (Logistics Management Information System) | Quarterly | 48% of facilities (400/826) | 75% | MOHCDGEC |
<table>
<thead>
<tr>
<th>No</th>
<th>Indicator</th>
<th>Indicator definition (numerator and denominator)</th>
<th>Disaggregation</th>
<th>Indicator source</th>
<th>Data source</th>
<th>Frequency</th>
<th>Baseline</th>
<th>Target</th>
<th>Stakeholder</th>
</tr>
</thead>
</table>
| 4.8| Disaggregation of health facilities with at least one clinical staff trained on rational use of HIV medicines and pharmacovigilance | **Numerator:** Number of health facilities with at least one clinical staff trained on rational use of HIV medicines and pharmacovigilance  
**Denominator:** Number of health facilities implementing HIV care and treatment services | By facility type (dispensary, health centre, hospital), facility ownership (public, private, FBO), geographic location | HBSIP III | transSMART | Quarterly | 9% (180/192) | 80% | MOHCDGE |

**Intervention area 4.3: Health facility commodity management and rational use of medicine**

**Strategic outcome 3: Commodity management and logistic information will be generated and used at different levels of the health delivery system to improve decision making**

| 4.9 | Percentage of HIV care and treatment facilities prescribing and dispensing ARVs/PIs according to national guidelines | **Numerator:** Number of HIV care and treatment facilities prescribing and dispensing ARVs/PIs according to national guidelines  
**Denominator:** Total number of health facilities implementing HIV care and treatment | By facility type | HBSIP IV 2017-2022 | Rational use of medicine assessment report | Annually | TBD | ARV/PIs: 80% | MOHCDGE |
| 4.10 | Percentage of ordering facilities submitting ARVs and laboratory logistics reports within a specified time limit | **Numerator:** Number of facilities submitting ARVs and laboratory logistics within a specified time limit  
**Denominator:** Number of facilities implementing HIV care and treatment services | By commodity system type (ARVs, and laboratory) | HBSIP IV | careMIS | N/A ARV and OIs reported quarterly; plans are underway to start reporting after every 2 months | ARV: 93%  
Lab: 90% | ARV: 100%  
Lab: 90% | MOH |
<table>
<thead>
<tr>
<th>No</th>
<th>Indicator</th>
<th>Indicator definition (numerator and denominator)</th>
<th>Disaggregation</th>
<th>Indicator source</th>
<th>Data source</th>
<th>Frequency</th>
<th>Baseline</th>
<th>Target</th>
<th>Stakeholder</th>
</tr>
</thead>
</table>
| 4.11 | Number of care and treatment facilities documenting ADRs and reporting TFD | **Numerator**: Number of care and treatment facilities documenting ADRs and reporting them to TFD  
**Denominator**: Number of care and treatment facilities. | By facility type | HSHSP IV | TFD | Quarterly | Not currently available | 60% | MOHCDGEC |
| 4.12 | Proportion of health facilities using pharmacovigilance reports at a facility level | **Numerator**: Number of health facilities using pharmacovigilance reports  
**Denominator**: Total number of health facilities implementing HIV care and treatment | By facility level | HSHSP IV | Rational use of medicine assessment report | Annually | TBD | 70% | MOHCDGEC, GHCTA, USAID |

**Intervention area 4.4: Laboratory services**

**Strategic outcome 5: Quality laboratory services provided for HIV/AIDS clients at all levels**

<table>
<thead>
<tr>
<th>No</th>
<th>Indicator</th>
<th>Indicator definition (numerator and denominator)</th>
<th>Disaggregation</th>
<th>Indicator source</th>
<th>Data source</th>
<th>Frequency</th>
<th>Baseline</th>
<th>Target</th>
<th>Stakeholder</th>
</tr>
</thead>
</table>
| 4.13 | Percentage of care and treatment hospital and health centre laboratories enrolled in SLMTA process according to the WHO/ARO (SLMTA) quality assurance standards | **Numerator**: Number of laboratories which meet quality assurance standards for enrolment in SLMTA  
**Denominator**: Number of care and treatment hospitals (N = 241) and health centres (N = 585) | By facility type | WHO/SLMTA Guidelines 2015 | SLMTA Report | Annually | National, zonal, and specialised hospitals: 7  
Region: 24  
District: 25 | Hospitals: 80%  
Health centres: 10% | MOHCDGEC, WHO, CDC, USAID, DCD, and IPs |
<table>
<thead>
<tr>
<th>No</th>
<th>Indicator</th>
<th>Indicator definition (numerator and denominator)</th>
<th>Disaggregation</th>
<th>Indicator source</th>
<th>Data source</th>
<th>Frequency</th>
<th>Baseline</th>
<th>Target</th>
<th>Stakeholder</th>
</tr>
</thead>
</table>
| 4.14 | Percentage of hospital and health centre laboratories enrolled in SLMTA process which achieved star rank according to the WHO/ARRO (SLIPA) quality assurance standards | **Numerator**: Number of laboratories which meet quality assurance standards and achieve at least one star rank  
**Denominator**: Number of care and treatment hospitals and health laboratories enrolled in the SLMTA programme | By facility type (dispersary, health centre, hospital), facility ownership (public, private, FBO), geographic location | WHO | Country SUMTA report | Annually | National, zonal, and specialised hospitals, 5  
Regional, district, FBO, private, and military hospitals, 25  
Health centres, 0 | Hospitals: 80%  
Health centres: 10% | MOHCDGEC, WHO, CHAI, CDC, USAID, DOD, and IPs |
| 4.15 | Percentage of health facilities offering ART (CTC and PMCTC) that provide both VL and ED testing services through conventional and POC testing | **Numerator**: Number of health facilities offering ART that provide both VL and ED services  
**Denominator**: Number of health facilities offering ART services (CTC and PMCTC); Hospitals N = 241; health centres, N = 585; dispensaries, N = 1,100 | By facility type (hospital, health centre, dispensary), facility ownership (public, private, FBO), geographic location, type of test (ED or FLM) | HSHP IV  
LS (Lab Information System) and PMCTC annual report | Quarterly | Hospitals: 90%  
Health centres: 70%  
Dispensaries: 50% | Hospitals: 99%  
Health centres: 95% by 2022  
Dispensaries: 80% by 2022 | MOHCDGEC, CHAI, WHO, CDC, USAID, DOD, and IPs |
<table>
<thead>
<tr>
<th>No.</th>
<th>Indicator</th>
<th>Indicator definition (numerator and denominator)</th>
<th>Disaggregation</th>
<th>Indicator source</th>
<th>Data source</th>
<th>Frequency</th>
<th>Baseline</th>
<th>Target</th>
<th>Stakeholder</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.16</td>
<td>Percentage of BD and HVL tests conducted at care and treatment laboratories against the annual targets</td>
<td><strong>Numerator</strong>: Number of BD and HVL tests conducted at care and treatment laboratories. <strong>Denominator</strong>: Targeted number of BD and HVL tests per year.</td>
<td>By facility type (hospital, health centre, dispensary) facility, ownership (public, private, FBO), geographic location (BD and HVL).</td>
<td>HSHSP IV</td>
<td>Open Laboratory Data Repository</td>
<td>Quarterly</td>
<td>HVL: 80% BD: 33%</td>
<td>HVL: 98% BD: 90%</td>
<td>MOH, CDC, CHAI, and IPs</td>
</tr>
</tbody>
</table>

| 4.17| Percentage of care and treatment laboratories that submit timely LIS reports (HVL, BD, CD4, syphilis, cryptococcus, chemistry, and haematology) | **Numerator**: Number of care and treatment hospital and health centre laboratories that submitted LIS reports. **Denominator**: Total number of care and treatment hospital and health centre laboratories. | Disaggregated by level: national/specialised/zonal/regional, district, FBO, military, private hospital, health centre, geographic location. | HSHSP IV | Open LDR (NHLQAIC) | Quarterly | National/ specialised/zonal/regional: 80% | District/FBO/military and private: 50% | Health centres: 20% | MOH, CDC, and FO-RALG |

**Intervention area 4.5: Healthcare equipment maintenance (laboratory equipment)**

**Strategic outcome 6: Uninterrupted HIV services as a result of timely PPM of laboratory and other healthcare equipment**

<p>| 4.18| Percentage of laboratory equipment covered by PPM system | <strong>Numerator</strong>: Number of laboratory equipment on PPM contract. <strong>Denominator</strong>: Total number of laboratory equipment identified for PPM. | Disaggregated by test panel (HVL, BD, CD4, chemistry and haematology) and testing platform. | HSHSP IV | Open Laboratory Data Repository (Open LDR) | Biannually | HVL/BD: 90% CD: 40% chemistry: 35% haematology: 35% | HVL/BD: 98% CD: 90% Chemistry: 70% Haematology: 70% | MOH, CD, USAID, DCD, and IPs |</p>
<table>
<thead>
<tr>
<th>No</th>
<th>Indicator</th>
<th>Indicator definition (numerator and denominator)</th>
<th>Disaggregation</th>
<th>Indicator source</th>
<th>Data source</th>
<th>Frequency</th>
<th>Baseline</th>
<th>Target</th>
<th>Stakeholder</th>
</tr>
</thead>
</table>
| 4.19 | Percentage of equipment at care and treatment facilities or laboratories reported as broken down in a given period | **Numerator:** Numbers of equipment at care and treatment facilities laboratories reported as broken down in a given period  
**Denominator:** Numbers of equipment at care and treatment hospital and health centre laboratories  
| Disaggregate by type of test and level of facility  
HM/ED; CD4; Haematology; Chemistry | HSHSP IV | Open LDR | Monthly | HM/ED; CD4; Haematology; Chemistry (Pavel/Bahati) | MOHCDGEC, CDC, USAID, DOD, and IPs |

| 4.20 | Percentage of average time the laboratory equipment at care and treatment facilities functioning per quarter against minimal requirements | **Numerator:** Average time the laboratory equipment at care and treatment facilities are functioning  
**Denominator:** Standard functioning time of equipment at care and treatment hospital and health centre laboratories  
| Disaggregate by type of test and level of facility  
HM/ED; CD4; Haematology; Chemistry | HSHSP IV | Open LDR | Quarterly | HM/ED; CD4; Haematology; Chemistry | MOHCDGEC, CDC, USAID, DOD, and IPs |

**Intervention area 4.6: HIV strategic information**

**Strategic outcome 7:** A well-regulated, monitored, and evaluated programme with up-to-date research outcomes relevant for HIV and AIDS, and that addresses improved data quality and informs programme performance

| 4.21 | Proportion of RHMTs/CHMTs with a government employee designated to perform M&E functions | **Numerator:** Number of RHMTs/CHMTs with a government employee designated to perform M&E functions  
**Denominator:** Total number of RHMTs/CHMTs  
<p>| By regions and districts | HSHSP IV | FORALG workforce database | Annually | None | 50% (2022) | FORALG/ MOHCDGEC |</p>
<table>
<thead>
<tr>
<th>No</th>
<th>Indicator</th>
<th>Indicator definition (numerator and denominator)</th>
<th>Disaggregation</th>
<th>Indicator source</th>
<th>Data source</th>
<th>Frequency</th>
<th>Baseline</th>
<th>Target</th>
<th>Stakeholder</th>
</tr>
</thead>
</table>
| 422| Percentage of facilities providing HIV services with timely submission of reports into the DHS | **Numerator:** Number of facilities providing HIV services with timely submission of reports into the DHS  
**Denominator:** Total number of facilities providing HIV services | By HIV interventions (HTS, ART, PMTCT, CBHS, VMMC, STI) | HSPH IV; GF  
Health Systems Strengthening (HSS) M&E Plan | DHS           | Quarterly/monthly | CIC/ART: 87% | 100% (2022) | MOHCDGEC |
| 423| Percentage of health facilities providing ART services with electronic data management systems (CTC database) | **Numerator:** Percentage of health facilities providing ART services with electronic data management systems (CTC database)  
**Denominator:** Number of health facilities providing ART (including Option B+) | By level of facility | HSPH IV | DHS | Annually | 1,701/6,259 (27%) | 95% | MOHCDGEC |

**Intervention area 4.8: Community-based health system (CBHS)**

**Strategic outcome 8: Strengthened community participation for quality CBHS**

<table>
<thead>
<tr>
<th>No</th>
<th>Indicator</th>
<th>Indicator definition (numerator and denominator)</th>
<th>Disaggregation</th>
<th>Indicator source</th>
<th>Data source</th>
<th>Frequency</th>
<th>Baseline</th>
<th>Target</th>
<th>Stakeholder</th>
</tr>
</thead>
</table>
| 424| Percentage of PLHIV on care and treatment enrolled in CBHS                  | **Numerator:** Number of PLHIV on care and treatment enrolled in CBHS  
**Denominator:** Total number of PLHIV on care and treatment services | Sex, age | HSPH IV | DHS | Monthly | 51.2% (507,479/990,699) | 90% | LGA, NACP, MOHCDGEC, development partners |
<p>| 425| Percentage of missed appointment/LTFU clients followed up and linked back to health facility | <strong>Numerator:</strong> Number of missed appointments/LTFU clients linked back to health facility services by CBHS providers | Type of clinic (RCH, CI) | HSPH IV | HIMS | Monthly | None | 90% | LGA, NACP, IPs, development partners |</p>
<table>
<thead>
<tr>
<th>No</th>
<th>Indicator</th>
<th>Indicator definition (numerator and denominator)</th>
<th>Disaggregation</th>
<th>Indicator source</th>
<th>Data source</th>
<th>Frequency</th>
<th>Baseline</th>
<th>Target</th>
<th>Stakeholder</th>
</tr>
</thead>
</table>
| 4.26 | Percentage of care and treatment facilities with a designated CBHS provider or supervisor | **Numerator:** Number of care and treatment facilities with a designated CBHS provider or supervisor  
**Denominator:** Total number of care and treatment facilities | By facility level | HSHSP IV | DHS/NACP CBHS report | Annual | 48% | 90% | MOHCDGEC |

**STRATEGIC AREA 5: Cross-sector HIV and AIDS interventions and other innovative investments**

**Intervention area 5.1: Stigma, discrimination, and gender-based violence (GBV)**

**Strategic outcome 1:** Proportion of PLHIV who reported experiencing stigma and discrimination from healthcare providers reduced from 40% to zero by 2022

| 5.1 | Percentage of women and men ages 15+ expressing specific attitudes towards people with HIV and AIDS | **Numerator:** Number of women and men ages 15+ expressing specific attitudes towards people with HIV and AIDS  
**Denominator:** Number of women and men ages 15+ surveyed | Male and female, age, education, residence | IHIS | IHIS 2016–2017 | 5 yrs | Men: 40%  
Women: 25% | 100% | MOH, NBS, TACAIDS |
| 5.2 | Percentage of PLHIV who experienced or perceived stigma when accessing health services | **Numerator:** Number of PLHIV who reported experiencing stigma when accessing HIV services  
**Denominator:** Total number of PLHIV surveyed | Sex, age, residence | IHIS | IHIS 2016–2017 | 5 yrs | TBD | 0% | TACAIDS, MOHCDGEC, NACP, NACOPHA |
<table>
<thead>
<tr>
<th>No</th>
<th>Indicator</th>
<th>Indicator definition (numerator and denominator)</th>
<th>Disaggregation</th>
<th>Indicator source</th>
<th>Data source</th>
<th>Frequency</th>
<th>Baseline</th>
<th>Target</th>
<th>Stakeholder</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.2</td>
<td>Targeted social and behaviour change communication (SBCC)</td>
<td></td>
<td></td>
<td></td>
<td>GHPR: GP M&amp;E toolkit</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.3</td>
<td>Percentage of women and men ages 15-24 who correctly identify both ways of preventing the sexual transmission of HIV and reject major misconceptions about HIV transmission</td>
<td>Numerator: Number of respondents ages 15-24 who correctly answered all five questions</td>
<td>Sex, age, residence</td>
<td>IHIS 2016-2017</td>
<td>5 yrs</td>
<td>Males: 37%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Denominator: Number of all respondents ages 15-24</td>
<td></td>
<td></td>
<td></td>
<td>Females: 36.7%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.4</td>
<td>Percentage of young women and men ages 15-24 who have had sexual intercourse before the age of 15</td>
<td>Numerator: Number of respondents ages 15-24 who had sexual intercourse before age 15</td>
<td>Age, sex, residence</td>
<td>IHIS, UNGASS</td>
<td>Every 3-5 yrs</td>
<td>Males: 14.7%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Denominator: Number of all respondents ages 15-24</td>
<td></td>
<td></td>
<td></td>
<td>Females: 9.3%</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Intervention area 5.3: Health sector workplace interventions**

| 5.5 | Number of health sector institutions implementing workplace HIV interventions | Numerator: Number of enterprises implementing an HIV and AIDS workplace programme, providing at least one of the 4 critical components | Type of health sector institution, training institution, ministerial departments and agencies, healthcare facilities, etc. | HPH/ARNG NI P101.1D, HSHSP IV | Workplace survey | Annually | None | None | MOHCDGEC, TACADS |
| | | Denominator: NA |  |  |  |  |  |  |  |  |
### Intervention area 5.4: Adolescents and young people

#### Strategic outcome 5: Reduction of new HIV infection amongst adolescents and young women by 50% by 2022

#### Strategic outcome 6: 95% of adolescents living with HIV will be on ART by 2022

<table>
<thead>
<tr>
<th>No</th>
<th>Indicator</th>
<th>Indicator definition (numerator and denominator)</th>
<th>Disaggregation</th>
<th>Indicator source</th>
<th>Data source</th>
<th>Frequency</th>
<th>Baseline</th>
<th>Target</th>
<th>Stakeholder</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.6</td>
<td>Percentage of adolescents and youth who receive HTS and then their test results</td>
<td>None</td>
<td>Sex male vs. female; age ranges (15-19; 20-24); marital status; geographic area</td>
<td>TAS-HS-SP III 2017-2022</td>
<td>HIS database</td>
<td>Annually</td>
<td>Not available</td>
<td>50% (2022)</td>
<td>UNICEF, MOH/CDGEC</td>
</tr>
</tbody>
</table>

### Intervention area 5.5: Male involvement

#### Strategic outcome 7: Improved male involvement in HIV prevention, care, treatment, and support for their own health and the health of their partners and families

Refer to Indicator 1.2: Proportion of individuals who test for HIV as couples

Refer to Indicator 3.14: Proportion of male partners of pregnant mothers tested for HIV and who know their HIV status

### Intervention area 5.6: Gender-based violence

#### Strategic outcome 8: Reduce HIV-associated sexual and GBV

#### Strategic outcome 9: Mitigate effects of GBV on survivors, especially women and young people

<table>
<thead>
<tr>
<th>5.7</th>
<th>Proportion of men and women ages 15-49 who Number of ever married or partnered men and women ages</th>
<th>Age, sex, residence</th>
<th>GARP</th>
<th>DHS2</th>
<th>Annual</th>
<th>FEMALES: 47,719</th>
<th>TBID</th>
<th>TACADS, MOH/CDGEC</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>Indicator</td>
<td>Indicator definition (numerator and denominator)</td>
<td>Disaggregation</td>
<td>Indicator source</td>
<td>Data source</td>
<td>Frequency</td>
<td>Baseline</td>
<td>Target</td>
</tr>
<tr>
<td>----</td>
<td>-----------</td>
<td>--------------------------------------------------</td>
<td>----------------</td>
<td>-----------------</td>
<td>-------------</td>
<td>-----------</td>
<td>----------</td>
<td>--------</td>
</tr>
</tbody>
</table>
|    | experienced physical or sexual violence in the past 12 months | 15-49 who experienced physical or sexual violence from a male intimate partner in the past 12 months  
**Denominator:** Total number of women ages 15-49 surveyed | | | | | | | |
| 58 | Proportion of sexually abused clients receiving HIV PEP | Numerator: Number of sexually abused clients receiving HIV PEP  
**Denominator:** Number of all clients reported sexually abused | Age, sex, residence | HBS 2 | Monthly | | | TAACS, MOHCDGEC |
| 59 | Proportion of sexually and physically abused clients tested for HIV | Numerator: Number of sexually abused clients tested for HIV  
**Denominator:** Number of all clients reported sexually abused | Age, sex, residence | HBS 2 | Monthly | | | TAACS, MOHCDGEC |
### APPENDIX 3. HEALTH SECTOR M&E SYSTEM STRENGTHENING ACTION PLAN

<table>
<thead>
<tr>
<th>M&amp;E system component</th>
<th>Specific activities</th>
<th>Timeline</th>
<th>Responsibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Organisational structure for M&amp;E</td>
<td>1.1. Fill in all M&amp;E posts within NACP’s national and subnational structures</td>
<td>2018</td>
<td>NACP; POPSM; FORALG</td>
</tr>
<tr>
<td></td>
<td>1.2. Advocate with the POPSM and FORALG for the finalisation of a scheme of service for council-level M&amp;E officers to improve health sector HIV/AIDS services data collection, quality, and use</td>
<td>2018</td>
<td>NACP</td>
</tr>
<tr>
<td></td>
<td>1.3. Strengthen the capacity of council and regional HMS focal persons on HIV data systems, including in DHS 2 data analysis, visualisation, and presentation</td>
<td>Ongoing</td>
<td>NACP</td>
</tr>
<tr>
<td></td>
<td>1.4. Strengthen collaboration with implementing partners in the implementation of M&amp;E activities for the health sector HIV response</td>
<td>Ongoing</td>
<td>NACP</td>
</tr>
<tr>
<td></td>
<td>1.4.1. Conduct annual HIV workplan development workshop with implementing partners</td>
<td>March–May each year</td>
<td>NACP</td>
</tr>
<tr>
<td></td>
<td>1.4.2. Conduct quarterly HIV programme performance review with implementing partners</td>
<td>Quarterly</td>
<td>NACP</td>
</tr>
<tr>
<td></td>
<td>1.5. Promote and strengthen regional M&amp;E TWGs as a forum for reviewing performance against the HSHSP IV indicators and addressing data quality and data use challenges</td>
<td>2018</td>
<td>NACP; RHMs; CHMI</td>
</tr>
<tr>
<td></td>
<td>1.5.1. Develop terms of reference for regional M&amp;E TWGs</td>
<td>July 2018</td>
<td>NACP</td>
</tr>
<tr>
<td></td>
<td>1.5.2. Establish a secretariat for regional M&amp;E TWGs</td>
<td>Sep. 2018</td>
<td>RHMs; CHMI</td>
</tr>
<tr>
<td></td>
<td>1.5.3. Conduct quarterly regional M&amp;E TWG meetings</td>
<td>Oct. 2018, then quarterly</td>
<td>NACP; RHMs; CHMI</td>
</tr>
<tr>
<td>2. Human capacity</td>
<td>2.1. Assess knowledge and skills amongst regional and council-level HIV/AIDS M&amp;E focal persons and develop capacity building plan as appropriate</td>
<td>2018–2019</td>
<td>NACP</td>
</tr>
<tr>
<td>Section</td>
<td>Activity Description</td>
<td>Start Date</td>
<td>Responsible Party</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------</td>
<td>------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>2.1.2</td>
<td>Develop customised training packages for regional and council-level HIV/AIDS M&amp;E focal persons</td>
<td>Dec. 2018</td>
<td>NACP</td>
</tr>
<tr>
<td>2.1.3</td>
<td>Conduct training for regional and council-level HIV/AIDS M&amp;E focal persons</td>
<td>Jan.–July 2019</td>
<td>NACP</td>
</tr>
<tr>
<td>2.2</td>
<td>Promote the use of the training system monitoring and reporting tool (TrainSMART) in tracking all HIV/M&amp;E training activities</td>
<td>2018</td>
<td>NACP, MOHCDGEC</td>
</tr>
<tr>
<td>2.2.1</td>
<td>Provide access to trainSMART database for all councils within the country</td>
<td>July 2018</td>
<td>NACP, MOHCDGEC</td>
</tr>
<tr>
<td>2.2.2</td>
<td>Appoint a trainSMART database focal person for each council</td>
<td>Dec. 2018</td>
<td>NACP, MOHCDGEC</td>
</tr>
<tr>
<td>2.2.3</td>
<td>Conduct orientation training for trainSMART focal persons</td>
<td>2019</td>
<td>NACP, MOHCDGEC</td>
</tr>
<tr>
<td>2.3</td>
<td>Review the curriculum for medical records and determine scope for adding health sector HIV and M&amp;E contents</td>
<td>2018</td>
<td>NACP</td>
</tr>
<tr>
<td>3.1</td>
<td>Strengthen the NACP national health sector HIV/M&amp;E subcommittee as a platform for engaging with stakeholders</td>
<td>2018</td>
<td>NACP</td>
</tr>
<tr>
<td>3.1.1</td>
<td>Review the terms of reference for the NACP national health sector HIV/M&amp;E subcommittee</td>
<td>2018</td>
<td>NACP</td>
</tr>
<tr>
<td>3.1.2</td>
<td>Streamline MOHCDGEC M&amp;E Strengthening Initiative (MESI) and NACP national health sector HIV/M&amp;E subcommittee meeting schedules</td>
<td>2018</td>
<td>NACP, MOHCDGEC</td>
</tr>
<tr>
<td>3.2</td>
<td>Develop a regular (quarterly) newsletter as a tool for stakeholder engagement</td>
<td>Ongoing</td>
<td>NACP</td>
</tr>
<tr>
<td>3.3</td>
<td>Actively participate in the MOHCDGEC M&amp;E M &amp; T W G meetings</td>
<td>Ongoing</td>
<td>NACP</td>
</tr>
<tr>
<td>3.3.1</td>
<td>Assign an NACP M&amp;E subcommittee member to attend all MOHCDGEC M &amp; E T W G meetings</td>
<td>Ongoing</td>
<td>NACP</td>
</tr>
<tr>
<td>4.1</td>
<td>Develop data collection tools and data management guidelines for condom distribution, IEC, and KPs programmes</td>
<td>2018</td>
<td>NACP</td>
</tr>
<tr>
<td>4.2</td>
<td>Establish and strengthen monitoring and reporting of financial resources and investments of both the government and implementing partners for the health sector HIV response</td>
<td>2018</td>
<td>NACP, POFALG</td>
</tr>
<tr>
<td>5.1</td>
<td>Conduct demonstration studies to determine the operational and implementation strategies required to roll out PEP and HIV self-testing interventions amongst different populations in Tanzania</td>
<td>2018-2019</td>
<td>NACP, NBS</td>
</tr>
<tr>
<td>5.1.1.</td>
<td>Create a study advisory committee</td>
<td>2018</td>
<td>NACP, NBS</td>
</tr>
<tr>
<td>5.1.2.</td>
<td>Develop study protocols</td>
<td>2018</td>
<td>NACP, NBS</td>
</tr>
<tr>
<td>5.1.3.</td>
<td>Conduct the demonstration studies in selected sites</td>
<td>2018-2019</td>
<td>NACP, NBS</td>
</tr>
<tr>
<td>5.2.</td>
<td>Conduct integrated biological and behavioural surveillance surveys every two years as per protocol</td>
<td>2019-2021</td>
<td>NACP, NBS</td>
</tr>
<tr>
<td>5.2.1.</td>
<td>Create a study advisory committee</td>
<td>2019</td>
<td>NACP, NBS</td>
</tr>
<tr>
<td>5.2.2.</td>
<td>Develop a study protocol</td>
<td>2019</td>
<td>NACP, NBS</td>
</tr>
<tr>
<td>5.2.3.</td>
<td>Conduct the IBBS study in selected sites</td>
<td>2019</td>
<td>NACP, NBS</td>
</tr>
<tr>
<td>5.3.</td>
<td>Conduct workplace intervention surveys</td>
<td>2019</td>
<td>NACP, NBS</td>
</tr>
<tr>
<td>5.3.1.</td>
<td>Develop study protocol</td>
<td>2019</td>
<td>NACP</td>
</tr>
<tr>
<td>5.3.2.</td>
<td>Implement workplace intervention surveys</td>
<td>2019</td>
<td>NACP</td>
</tr>
<tr>
<td>6.1.1.</td>
<td>Harmonize import and export functionalities of all existing HIV databases (CTC2, HBS, HTC, STI, PMCT) with the DHS2</td>
<td>2018</td>
<td>NACP, MOHCDGC</td>
</tr>
<tr>
<td>6.2.</td>
<td>Develop a database for the R+5 programme</td>
<td>2018</td>
<td>NACP</td>
</tr>
<tr>
<td>7.</td>
<td>Evaluation and research</td>
<td>7.1.</td>
<td>Develop an inventory of HIV/AIDS research and evaluation</td>
</tr>
<tr>
<td>7.2.</td>
<td>Develop a health sector HIV research and evaluation agenda</td>
<td>2018</td>
<td>NACP</td>
</tr>
<tr>
<td>7.3.</td>
<td>Develop and disseminate policy briefs on major research studies completed</td>
<td>Ongoing</td>
<td>NACP</td>
</tr>
</tbody>
</table>